Systems and methods related to competition and mutualism in the dysbiotic vaginal microbiome
By analyzing the taxonomic and metabolic profiles of BV-associated bacteria, this method identifies cooperative and competitive species, providing insights into novel therapeutic candidates for bacterial vaginosis.
Patent Information
- Application Number
- PCT/US2024/050543
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-09
- Filing Date
- 2024-10-09
- Publication Date
- 2025-04-17
AI Technical Summary
Current therapies for bacterial vaginosis (BV) are limited due to a lack of understanding of the microbial community structure and metabolic interactions associated with the condition, hindering the development of targeted novel therapeutics.
The method involves determining the taxonomic bacterial composition and superorganism-level functional metabolic capacity from metagenomic sequencing data of symptomatic and asymptomatic BV samples, identifying differential metabolic pathways, and segregating gene content based on disease status to identify cooperative and competitive bacterial species.
This approach enables the identification of novel therapeutic candidates by elucidating the metabolic interactions between bacterial species, potentially leading to more effective treatments for BV.
Smart Images

Figure US2024050543_17042025_PF_FP_ABST
Abstract
Description
[0001] SYSTEMS AND METHODS RELATED TO COMPETITION AND MUTUALISM IN THE DYSBIOTIC VAGINAL MICROBIOME
[0002] CROSS REFERENCE TO RELATED APPLICATION[S]
[0003] This application claims priority to, and the benefit of, U.S. Provisional Patent Application Serial No. 63 / 543,142 filed on October 9, 2023, which is incorporated herein by reference in its entirety as if fully set forth herein.
[0004] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0005] This invention was made with Government support under contracts 2021791 awarded by the National Science Foundation and GB10853.40410 awarded by the National Institutes of Health. The Government has certain rights in the invention.
[0006] BACKGROUND
[0007] Bacterial vaginosis (BV) is the most prevalent vaginal condition among reproductive- age women experiencing vaginal complaints. Despite its significant impact on women's health, limited knowledge exists regarding the microbial community structure and metabolic interactions associated with BV. This lack of knowledge hinders the development of more targeted novel therapies, for example and without intending to be limiting, small molecules, nucleic acid therapies, protein therapies, and bacteriotherapies. Accordingly, there is a need to address the aforementioned deficiencies and inadequacies.
[0008] SUMMARY
[0009] Described herein are systems, methods, and computer readable media related to the identification of novel therapeutics, in particular, novel therapeutics for a dysbiotic vaginal microbiome that may lead to such conditions as symptomatic bacterial vaginosis. As would be understood from the present disclosure, any method involving any combination of steps can be stored as instructions on any non-transitory computer readable media or can be executed by any system as described herein.
[0010] Described herein are methods relating to the identification of novel therapeutics. In an embodiment, a method of identifying candidate therapeutics for administration against a candidate bacterial infection, comprises: determining, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determining, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; optionally determining, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control; determining superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data; identifying metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities; clustering the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities; annotating the gene content of each cluster; quantifying the annotated gene content; segregating the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status; identifying genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples; reconstructing the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition; segregating the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species; and identifying the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species.
[0011] In embodiments, the asymptomatic metagenomic sequencing data of the candidate bacterial infection is the same data as the optional metagenomic sequencing data of a healthy control. In embodiments, candidate bacterial infection is Bacterial Vaginosis (BV).
[0012] In embodiments, methods as described herein further comprise, before determining the taxonomic composition: providing one or more samples of the symptomatic bacterial infection from one or more donors; providing one or more samples of the asymptomatic bacterial infection from one or more donors; optionally providing one or more healthy samples from one or more healthy donors and sequencing the metagenome of the one or more samples of the symptomatic bacterial infection, the metagenome of the one or more samples of the asymptomatic bacterial infection, and optionally the metagenome of the one or more samples of the healthy donor[s].
[0013] In embodiments, the one or more symptomatic samples, one or more asymptomatic samples, and optional one or more healthy samples are vaginal swabs. In embodiments, symptomatic status is determined by the presence of excessive discharge and vulvovaginal pruritus. In embodiments, asymptomatic status is determined by the absence of excessive discharge and vulvovaginal pruritus. In embodiments, the metagenomic sequencing comprises shotgun sequencing, 16S rRNA sequencing, inferred from metatranscriptome, next-gen sequencing methods, using the 16S rRNA gene as a phylogenetic marker, or shotgun sequencing.
[0014] In embodiments, the superorganism-level functional capacity of methods according to the present disclosure is determined by: assembling contiguous genomic sequences from the metagenomic sequencing data; annotating gene content by assigning functional pathways to the assembled genomic sequences; mapping metagenomic reads to annotated genes; and differentiating functionalities of the mapped metagenomic reads. In embodiments, segregating the quantified gene content is using machine learning. In embodiments, the machine learning is a random forest or support vector machine. In embodiments, reconstructing the metabolism and segregating the reconstructed metabolism is with genome-scale metabolic network reconstructions.
[0015] In embodiments, methods according to the present disclosure further comprise culturing the primary bacterial candidate species; culturing the one or more identified cooperative secondary candidate bacterial species, one or more identified competitive secondary candidate bacterial species, or one or more one or more identified cooperative secondary candidate bacterial species and one or more competitive secondary candidate bacterial species; generating culture metabolomic data of the primary bacterial candidate species culture and each secondary culture; and identifying, from the culture metabolomic data, metabolites from each secondary culture that are dysregulated compared to the primary bacterial candidate species culture.
[0016] In embodiments, methods according to the present disclosure further comprise coculturing the primary bacterial candidate species with one or more identified cooperative secondary candidate bacterial species, one or more identified competitive secondary candidate bacterial species, or one or more one or more identified cooperative secondary candidate bacterial species and one or more competitive secondary candidate bacterial species; generating metabolomic data of the co-culture; and identifying, from the culture metabolomic data and co-culture metabolomic data, metabolites from each co-culture that are dysregulated compared to the primary bacterial candidate species culture, each secondary candidate bacterial species culture, or any combination of any thereof. In embodiments, identifying the dysregulated metabolites comprises a fold-change analysis. In embodiments, identifying one or more ligands of each identified dysregulated metabolite. In embodiments, the primary bacterial candidate species is a Gardnerella species.
[0017] Also described herein are systems. In an embodiment, a system as described herein comprises: a computing device comprising a processor and a memory; and machine-readable instructions stored in the memory that, when executed by the processor, cause the computing device to at least: determine, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determine, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; optionally determine, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control; determine superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data; identify metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities; cluster the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities; annotate the gene content of each cluster; quantify the annotated gene content; segregate the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status; identify genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples; reconstruct the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition; segregate the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species; and identify the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species. In embodiments, the asymptomatic metagenomic sequencing data of the candidate bacterial infection is the same data as the optional metagenomic sequencing data of a healthy control. In embodiments, the candidate bacterial infection is Bacterial Vaginosis (BV).
[0018] In embodiments, the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least, before a determination of the taxonomic composition: sequence the metagenome of the one or more samples of the symptomatic bacterial infection from provided symptomatic data, the metagenome of the one or more samples of the asymptomatic bacterial infection from provided asymptomatic data, and optionally the metagenome of the one or more samples of the healthy data. In embodiments, all of the provided data is derived from vaginal swabs. In embodiments, disease status (symptomatic, asymptomatic, and healthy) is determined by the presence or absence of excessive discharge and vulvovaginal pruritus. In embodiments, asymptomatic status is determined by the absence of excessive discharge and vulvovaginal pruritus. In embodiments, metagenomic sequencing comprises shotgun sequencing, 16S rRNA sequencing, inferred from metatranscriptome, next-gen sequencing methods, using the 16S rRNA gene as a phylogenetic marker, or shotgun sequencing.
[0019] In embodiments of systems as described herein, the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: determine superorganism-level functional capacity by assembling contiguous genomic sequences from the metagenomic sequencing data; annotating gene content by assigning functional pathways to the assembled genomic sequences; mapping metagenomic reads to annotated genes; and differentiating functionalities of the mapped metagenomic reads. In embodiments, segregating the quantified gene content is using machine learning. In embodiments, the machine learning is a random forest or support vector machine. In embodiments, reconstruction of the metabolism and segregating the reconstructed metabolism is with genome-scale metabolic network reconstructions.
[0020] In embodiments of systems as described herein, the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: identify, from provided culture metabolomic data, metabolites from each secondary culture that are dysregulated compared to the primary bacterial candidate species culture. In embodiments of systems described herein, identification of the dysregulated metabolites comprises a fold-change analysis. In embodiments of systems as described herein, the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: identify one or more ligands of each identified dysregulated metabolite. In embodiments, the primary bacterial candidate species is a Gardnerella species.
[0021] Also described herein are non-transitory, computer-readable medium, comprising machine-readable instructions that, when executed by a processor of a computing device, cause the computing device to at least: determine, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determine, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; optionally determine, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control; determine superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data; identify metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities; cluster the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities; annotate the gene content of each cluster; quantify the annotated gene content; segregating the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status; identify genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples; reconstruct the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition; segregate the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species; and identify the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species
[0022] BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Many aspects of the disclosed devices and methods can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the relevant principles. Moreover, in the drawings, like reference numerals designate corresponding parts throughout the several views.
[0024] FIG. 1 : Differential community composition of symptomatic vs. asymptomatic BV. FIG. 1 is A heatmap illustrating relative frequency of Gardnerella vaginalis co-occurrence with non-Gardnerella species in B symptomatic, BV asymptomatic, and healthy samples.
[0025] FIGs. 2A-2F: Pairwise in silico bacterial interactions. FIGs. 2A-2F are heatmaps illustrating primary bacteria biomass flux change in the presence of co-occurring bacteria when simulating (FIG. 2A) mutualism, (FIG. 2B) competition, (FIG. 2C) net interactions; t-SNE plots of primary bacteria biomass flux change reduced across all co-occurring bacteria when simulating (FIG. 2D) mutualism, (FIG. 2E) competition, (FIG. 2F) net interactions.
[0026] FIGs. 3A-3D: Relative competition versus mutualism and the metabolites that underly these interactions. (FIG. 3A) average biomass increase due to mutualism benefit vs. average biomass decrease due to competition cost for each bacteria (FIG. 3B) dendrogram of Gardnerella species, with light stars denoting top four most mutualistic bacteria and dark stars indicating top four most competitive bacteria across all interactions simulations (FIG. 3C) Most highly competed for (competition) and / or shared (mutualism) metabolites across all interaction simulations (FIG. 3D) G. piotii growth curves in NYC III enriched media (grey) and in NYC III enriched media supplemented with 0.1 % L-histidine (black), with mean and % standard deviation spread (one-tailed t-test, t=3.487, p-value < 0.01). FIGs. 4A-4D: Pairwise in vitro bacterial growth interactions. (FIGs. 4A-4H) depict growth curves in NYC III enriched media (black), spend G. piotii media (light pink), and spent G. vaginalis media (dark pink / red), with mean and two standard deviation spread. G. piotii and A. christensii have highly flocculent phenotypes.
[0027] FIGs. 5A-5F: Pairwise in vitro bacterial metabolic interactions. (FIGs. 5A-5E) Volcano plots of differential metabolites (blue: consumed; green: produced; gray: not significant) from co-occurring species grown in G. vaginalis spent media (FIG. 5F) Caffeic acid production of F. vaginae grown in G. piotii spent media versus NYC III (p-value = 0.07).
[0028] FIG. 6 is a is a block diagram illustrating an example of a machine upon which one or more aspects of embodiments of the present disclosure can be implemented.
[0029] FIG. 7 is a flowchart illustrating one example of a method according to various embodiments of the present disclosure.
[0030] DETAILED DESCRIPTION
[0031] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[0032] Although example embodiments of the present disclosure are explained in some instances in detail herein, it is to be understood that other embodiments are contemplated. Accordingly, it is not intended that the present disclosure be limited in its scope to the details of construction and arrangement of components set forth in the following description or illustrated in the drawings. The present disclosure is capable of other embodiments and of being practiced or carried out in various ways.
[0033] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit (unless the context clearly dictates otherwise), between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0034] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
[0035] Regarding machine hardware, it should be appreciated that any of the components or modules referred to with regards to any of the present invention embodiments discussed herein, may be integrally or separately formed with one another. Further, redundant functions or structures of the components or modules may be implemented. Moreover, the various components may be communicated locally and / or remotely with any user / operator / customer / client or machine / system / computer / processor. Moreover, the various components may be in communication via wireless and / or hardwire or other desirable and available communication means, systems and hardware. Moreover, various components and modules may be substituted with other modules or components that provide similar functions.
[0036] Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of genetics, microbiology, biochemistry, molecular biology, cellular biology, tissue culture, and the like.
[0037] Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.
[0038] Definitions
[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described herein.
[0040] As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” may include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a support” includes a plurality of supports. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
[0041] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently disclosed subject-matter. The term “about”, when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by “about” in that context, for example, ±5%, ±4%, ±3%, ±2%, etc.
[0042] Two events or entities are “associated” with one another, as that term is used herein, if the presence, level and / or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide, genetic signature, metabolite, microbe, etc.) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and / or form correlates with incidence of and / or susceptibility to the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically “associated” with one another if they interact, directly or indirectly, so that they are and / or remain in physical proximity with one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.
[0043] As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions can reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.
[0044] Those skilled in the art will appreciate that the term “composition”, as used herein, can be used to refer to a discrete physical entity that comprises one or more specified components. In general, unless otherwise specified, a composition can be of any suitable form - e.g., gel, liquid, solid, etc.
[0045] A composition or method described herein as "comprising" one or more named elements or steps is open-ended, meaning that the named elements or steps are essential to a particular aspect or embodiment, but other elements or steps can be added within the scope of the composition or method. To avoid prolixity, it is also understood that any composition or method described as "comprising" (or which "comprises") one or more named elements or steps also describes the corresponding, more limited composition or method "consisting essentially of' (or which "consists essentially of) the same named elements or steps, meaning that the composition or method includes the named essential elements or steps and can also include additional elements or steps that do not materially affect the basic and novel characteristic(s) of the composition or method. It is also understood that any composition or method described herein as "comprising" or "consisting essentially of one or more named elements or steps also describes the corresponding, more limited, and closed-ended composition or method "consisting of (or "consists of) the named elements or steps to the exclusion of any other unnamed element or step. In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step can be substituted for that element or step.
[0046] In this disclosure, "consisting essentially of or "consists essentially" or the like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like those disclosed herein, but which may contain additional structural groups, composition components or method steps (or analogs or derivatives thereof as discussed above). Such additional structural groups, composition components or method steps, etc., however, do not materially affect the basic and novel characteristic(s) of the compositions or methods, compared to those of the corresponding compositions or methods disclosed herein. "Consisting essentially of or "consists essentially" or the like, when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
[0047] As used herein, “Improved,” “increased” or “reduced,” or grammatically comparable comparative terms, indicate values that are relative to a baseline value or reference measurement. For example, in some embodiments, an assessed value achieved with an agent of interest may be “improved” relative to that obtained or expected in the absence of treatment or with a comparable reference agent or control. Alternatively, or additionally, in some embodiments, an assessed value achieved with an agent of interest may be “improved” relative to that obtained in the same subject or system under different conditions (e.g. , prior to or after an event such as administration of an agent of interest), or in a different, comparable subject (e.g., in a comparable subject or system that differs from the subject or system of interest). In some embodiments, comparative terms refer to statistically relevant differences (e.g., that are of a prevalence and / or magnitude sufficient to achieve statistical relevance). Those skilled in the art will be aware, or will readily be able to determine, in a given context, a degree and / or prevalence of difference that is required or sufficient to achieve such statistical significance.
[0048] As used herein, “isolated” means separated from constituents that otherwise may be present, for example, separated from bacterial stains or species that are not desired, or separating from other constituents that may be present with the micro-organisms in nature.
[0049] As used herein, the term “encode” refers to principle that DNA can be transcribed into RNA, which can then be translated into amino acid sequences that can form proteins
[0050] As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0051] As used herein, “individual”, "organism", "host", "subject", and “patient” refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single isolated eukaryotic cell or cultured cell or cell line, or as complex as a mammal, including a human being, and animals (e.g., vertebrates, amphibians, fish, mammals, e.g. , cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans). These terms (“individual,” “subject,” “host,” and “patient,” used interchangeably herein also refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. In embodiments, subject may relate to particular components of the subject, for instance specific tissues or fluids of a subject (e.g., human tissue in a particular area of the body of a living subject), which may be in a particular location of the subject, referred to herein as an "area of interest" or a "region of interest."
[0052] As used herein, “kit” means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
[0053] As used herein, “instruction(s)” means documents describing relevant materials or methodologies pertaining to a kit, or other things, for example, code to execute steps of methods as described herein in conjunction with a computing device. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents and are meant to include future updates.
[0054] Reference throughout this specification to “one embodiment’’, “an embodiment”, “another embodiment”, “some embodiment,” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” “in another embodiment”, or “in some embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but they may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some, but not other, features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention. For example, in the appended claims, any of the claimed embodiments can be used in any combination.
[0055] A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample or condition. For example, a test sample can include cells exposed to a test condition or a test agent, while the control is not exposed to the test condition or agent (e.g., negative control). The control can also be a positive control, e.g., a known primary cell or a cell exposed to known conditions or agents, for the sake of comparison to the test condition. A control can also represent an average value gathered from a plurality of samples, e.g., to obtain an average value. For therapeutic applications, a sample obtained from a patient suspected of having a given disorder or deficiency can be compared to samples from a known normal (non-deficient) individual. A control can also represent an average value gathered from a population of similar individuals, e.g., patient having a given deficiency or healthy individuals with a similar medical background, same age, weight, etc. A control value can also be obtained from the same individual, e.g., from an earlier-obtained sample, prior to the disorder or deficiency, or prior to treatment. One of skill will recognize that controls can be designed for assessment of any number of parameters.
[0056] The term “biological sample” encompasses a variety of sample types obtained from an organism or a cell line. The term encompasses blood and other liquid samples of biological origin, solid tissue samples, such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof. The term includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components. The term includes a clinical sample, and includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples. The term “clinical well-being” as used herein, refers to a state or degree of clinical or physiological wellness or health of a patient. A clinician can evaluate a patient’s clinical wellbeing by physical examination or performing one or more tests or assays.
[0057] The terms “therapy,” “treatment,” and “amelioration” refer to any reduction in the severity of symptoms, e.g., of a neurodegenerative disorder or neuronal injury. As used herein, the terms “treat” and “prevent” are not intended to be absolute terms. Treatment can refer to any delay in onset, amelioration of symptoms, improvement in patient survival, improved cognitive function or coordination, increase in survival time or rate, etc. The effect of treatment can be compared to an individual or pool of individuals not receiving the treatment, or to the same patient prior to treatment or at a different time during treatment. In some aspects, the severity of disease is reduced by at least 10%, as compared, e.g., to the individual before administration or to a control individual not undergoing treatment. In some aspects the severity of disease is reduced by at least 25%, 50%, 75%, 80%, or 90%, or in some cases, no longer detectable using standard diagnostic techniques.
[0058] As used throughout, the terms “nucleic acid,” “nucleic acid sequence,” “oligonucleotide,” “nucleotides,” or other grammatical equivalents as used herein mean at least two nucleotides, either deoxyribonucleotides or ribonucleotides, or analogs thereof, covalently linked together. Polynucleotides are polymers of any length, including, e.g., 20, 50, 100, 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A polynucleotide described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. The following are nonlimiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, cRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also includes both double- and single-stranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule. Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.
[0059] Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof, alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.
[0060] As used herein, “cDNA” refers to a DNA sequence that is complementary to an RNA transcript in a cell. It is a man-made molecule. Typically, cDNA is made in vitro by an enzyme called reverse-transcriptase using RNA transcripts as templates.
[0061] As used herein with reference to the relationship between DNA, cDNA, cRNA, RNA, protein / peptides, and the like “corresponding to” or “encoding” (used interchangeably herein) refers to the underlying biological relationship between these different molecules. As such, one of skill in the art would understand that operatively “corresponding to” can direct them to determine the possible underlying and / or resulting sequences of other molecules given the sequence of any other molecule which has a similar biological relationship with these molecules. For example, from a DNA sequence an RNA sequence can be determined and from an RNA sequence a cDNA sequence can be determined.
[0062] As used herein, “gene” can refer to a hereditary unit corresponding to a sequence of DNA that occupies a specific location on a chromosome and that contains the genetic instruction for a characteristic(s) or trait(s) in an organism. The term gene can refer to translated and / or untranslated regions of a genome. “Gene” can refer to the specific sequence of DNA that is transcribed into an RNA transcript that can be translated into a polypeptide or be a catalytic RNA molecule, including but not limited to, tRNA, siRNA, piRNA, miRNA, long- non-coding RNA and shRNA.
[0063] The word "expression" or "expressed" as used herein in reference to a gene means the transcriptional and / or translational product of that gene. The level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1-18.88).
[0064] The terms “polypeptide” and “peptide” are used interchangeably herein to refer to a polymer of amino acid residues in a single chain. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non- naturally occurring amino acid polymers. Amino acid polymers may comprise entirely L-amino acids, entirely D-amino acids, or a mixture of L- and D-amino acids. The term “protein” as used herein refers to either a polypeptide or a dimer (i.e., two) or multimer ( / .e., three or more) of single chain polypeptides. The single chain polypeptides of a protein may be joined by a covalent bond, e.g., a disulfide bond, or non-covalent interactions. The terms “portion” and “fragment” are used interchangeably herein to refer to parts of a polypeptide, nucleic acid, or other molecular construct.
[0065] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y- carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
[0066] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
[0067] The amino acids in the polypeptides described herein can be any of the 20 naturally occurring amino acids, D-stereoisomers of the naturally occurring amino acids, unnatural amino acids and chemically modified amino acids. Unnatural amino acids (that is, those that are not naturally found in proteins) are also known in the art, as set forth in, for example, Zhang et al. “Protein engineering with unnatural amino acids,” Curr. Opin. Struct. Biol. 23(4): 581-87 (2013); Xie et al. “Adding amino acids to the genetic repertoire, "Curr. Opin. Chem. Biol. 9(6): 548-54 (2005); and all references cited therein. Beta and gamma amino acids are known in the art and are also contemplated herein as unnatural amino acids.
[0068] In accordance with standard nomenclature, amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows, for example: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (He, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Vai, V). “Protein” and “Polypeptide” can refer to a molecule composed of one or more chains of amino acids in a specific order. The term protein is used interchangeable with “polypeptide.” The order is determined by the base sequence of nucleotides in the gene coding for the protein. Proteins can be involved in the structure, function, and regulation of various functions.
[0069] The term “identity” or “substantial identity,” as used in the context of a polynucleotide or polypeptide sequence described herein, refers to a sequence that has at least 60% sequence identity to a reference sequence. Alternatively, percent identity can be any integer from 60% to 100%. Exemplary embodiments include at least: 60%, 65%, 70%, 75%, 80%, 85%, 88%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, as compared to a reference sequence using the programs described herein; preferably BLAST using standard parameters, as described below. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.
[0070] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
[0071] A “comparison window,” as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith & Waterman Add. APL. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerized implementations of these algorithms (e.g., BLAST), or by manual alignment and visual inspection.
[0072] Algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-10 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (NCBI) web site. The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al. (1977)). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word size (W) of 28, an expectation (E) of 10, M=1 , N=-2, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word size (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
[0073] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.01 , more preferably less than about 105, and most preferably less than about 10’20.
[0074] The terms “bacterial population” or “bacterial consortium” as used herein refers to a homogeneous population of bacteria consisting of a single strain of a bacterial species or a heterogeneous population of bacteria consisting of at least two distinguishable strains of a single bacterial species or of a plurality of species.
[0075] The term "composition" as used herein refers to a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such a term in relation to a pharmaceutical composition is intended to encompass a product comprising the active ingredient(s) , and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation, or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present disclosure encompass any composition made by admixing a compound of the present disclosure and a pharmaceutically acceptable carrier.
[0076] The term "preventing" means to stop or hinder a disease, disorder, or symptom of a disease or condition through some action.
[0077] The term "probiotic" is recognized in the state of the art as a microorganism which, when administered in adequate amounts, confers a health benefit to the host. A probiotic microorganism must fulfil several requirements related to lack of toxicity, viability, adhesion and beneficial effects. These probiotic features are strain-dependent, even among bacteria of the same species. Therefore, it is important to find those strains that have a better performance in all probiotic requirements.
[0078] The term "reducing" means to diminish in extent, amount, or degree.
[0079] The term “therapeutic agent” as used herein refers to a therapeutic substance selected from a group consisting of, but not limited to, analgesics, anesthetics, anti-inflammatory agents, antiasthma agents, antibiotics (including penicillins), anticoagulants, antihistamines, antitussives, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antioxidant agents, antipyretics, immunosuppressants, immunostimulants, antiviral agents, bacteriostatic agents, bronchodilators, buffering agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, free radical scavenging agents, growth factors, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, proteins, peptides and polypeptides, prostaglandins, radio-pharmaceuticals, time release binders, anti-allergic agents, stimulants and anoretics, steroids, sympathomimetics, vasodilators, and xanthines.
[0080] The terms "treating" or "treatment" as used herein refers to an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression orworsening of those symptoms, or prevention or prophylaxis of the disease or disorder, or curing the disease or disorder. Similarly, as used herein, an "effective amount" or a "therapeutically effective amount" of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms or prevents or provides prophylaxis for the disorder or condition. Discussion
[0081] As described herein, metagenomic data obtained from human vaginal swabs was utilized to generate in silico predictions of BV-associated bacterial metabolic interactions via genome-scale metabolic network reconstructions (GENREs). While most efforts to type symptomatic BV (and thus guide therapeutic intervention by identifying responders and nonresponders to treatment) is based on genomic profiling, in silico simulations undertaken revealed functional metabolic relatedness between species as quite distinct from genetic relatedness. Several of the most common co-occurring bacteria (Prevotella amnii, Prevotella buccalis, Hoylesella timonensis, Lactobacillus iners, Fannyhessea vaginae, and Aerrococcus christenssii) were grown on the spent media of Gardnerella species and metabolomics was performed to identify potential mechanisms of metabolic interaction. For example, BV- associated bacteria that produce caffeate, a compound implicated in estrogen receptor binding, when grown in the spent media of other BV-associated bacteria was identified. These findings underscore the complex and diverse nature of BV-associated bacterial community structures and several of these mechanisms are of potential significance in understanding host-microbiome relationships.
[0082] Described herein are systems, methods, and computer readable medium for, among other things, predictive platforms for novel microbial therapeutics. Such systems, methods, and computer readable medium can be utilized for identifying bacterial species and candidate therapeutics for administration against a candidate bacterial infection in particular. Novel therapeutic candidates identified can be any number of therapeutic modalities, including one or more species of bacteria as a probiotic, or cellular components such as genes, mRNA, proteins ( / .e., ligand-activated receptors along the cell surface or in a sub-cellular compartment). In an embodiment, the bacterial infection is Bacterial Vaginosis (BV). An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms / models that enabled identification of putative therapeutic targets.
[0083] I. PLATFORMS FOR THERAPEUTIC TARGET IDENTIFICATION
[0084] Described herein are methods, systems, platforms, and machine-readable media relating to platforms to identify novel therapeutics for the treatment of various disorders, for example, a bacterial infection such as symptomatic or asymptomatic BV. In embodiments, the methodologies and platforms are related to novel therapeutics for BV.
[0085] A. Methodologies
[0086] Described herein are methods of identifying candidate therapeutics and therapeutic targets against a candidate bacterial infection. Through metagenomic sequencing and metabolomic analysis, bacterial populations that cooperate, compete, or otherwise effect net mass flux with one or more species of bacteria can be identified. Further metabolic analysis of these one or more species can further identify dysregulated metabolites that may underlie pathophysiology of the candidate bacterial infection. Identifying natural ligands or targets of these dysregulated metabolites can lead to novel putative therapeutic targets that can further be tested with novel therapeutics, for example, small molecules (less than 2500 daltons), protein and nucleic acid therapeutics, bacterial therapeutics ( / .e. probiotics in the form of one or more bacterial strains, or a consortium of such), or other cellular or gene-editing therapeutics.
[0087] In certain aspects, methodologies as described herein provide for at least: a) generating in silico predictions of BY-associated bacterial metabolic interactions via genomescale metabolic network reconstructions (GENRES), b) identifying potential targets for therapeutic interventions by investigating the competitive and mutualistic relationships among BV-associated bacteria, c) computational modeling to simulate thousands of pairwise interactions between bacterial species to analyze possible competitive and mutualistic behaviors, and d) utilizing mutualistic and competitive interactions between bacterial pairs, to identify the intricate microbial community associated with BV, thereby developing more effective treatments for this prevalent condition.
[0088] Methods as described herein can comprise determining, from provided metagenomic sequencing data of symptomatic bacterial infection samples, asymptomatic bacterial infection sections, and optionally healthy control bacterial samples, taxonomic bacterial composition of one or more samples a candidate bacterial infection. The samples can be collected from a mammalian subject, for example, a human biological female.
[0089] In embodiments, the candidate bacterial infection is a Bacterial Vaginosis (BV).
[0090] In embodiments, samples collected and analyzed, or the source of provided data, are derived from vaginal swabs ( / .e., microbiota from the vagina of a subject that is collected in a standard swab).
[0091] In embodiments, methods as described herein can further comprise sequencing the metagenome of the one or more biological samples (e.g., vaginal swabs of a subject as discussed above). In embodiments, the metagenomic sequencing comprises next-gen sequencing.
[0092] Methods as described herein can comprise determining superorganism-level functional metabolic capacity from the metagenomic sequencing data of the symptomatic, asymptomatic, and optional healthy group. In embodiments, the asymptomatic group is a healthy control group. In embodiments, the superorganism-level functional capacity can be determined by assembling contiguous genomic sequences from the metagenomic sequencing data; annotating gene content by assigning functional pathways to the assembled genomic sequences; mapping metagenomic reads to annotated genes; and differentiating functionalities of the mapped metagenomic reads.
[0093] Methods as described herein can comprise identifying metabolic pathways with differential metabolic capacities between the groups (symptomatic, asymptomatic, and optional healthy group) from the determined capacities.
[0094] Methods as described herein can comprise clustering the groups (symptomatic, asymptomatic, and optional healthy group) based on the identified determined functional metabolic capacities.
[0095] Methods as described herein can comprise annotating the gene content of each cluster.
[0096] Methods as described herein can comprise quantifying the annotated gene content.
[0097] Methods as described herein can comprise segregating the quantified gene content based on disease status (i.e., symptomatic, asymptomatic, or healthy control).
[0098] Methods as described herein can comprise identifying genes enriched in one or more metabolic pathways from the segregated quantified gene content.
[0099] Methods as described herein can comprise reconstructing the metabolism of the one or more metabolic pathways mapped onto one or more species from the determined taxonomic composition.
[0100] Methods as described herein can comprise segregating the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive with the candidate bacterial infection. In embodiments, segregating the quantified gene content is using machine learning. Machine learning can be utilized and / or implemented according to methods known in the art. In embodiments, the machine learning is supervised, semi-supervised, unsupervised or reinforcement. In embodiments, the machine learning utilizes random forests, support vector machines. In embodiments, the machine learning utilizes classification, regression, and / or clustering.
[0101] In embodiments, reconstructing the metabolism and segregating the reconstructed metabolism is with genome-scale metabolic network reconstructions (GENREs). GENREs are comprehensive mathematical representations of metabolic reactions in a cell. GENREs include the mapping of gene annotation to reaction stoichiometry and capture the stoichiometry as a mathematical matrix. Additional information relating to GENREs can be found, for example, in Bauer, E. & Thiele, I. From Network Analysis to Functional Metabolic Modeling of the Human Gut Microbiota. mSystems 3, e00209-17 (2018); Bauer, E. & Thiele, I. From metagenomic data to personalized in silico microbiotas: predicting dietary supplements for Crohn’s disease. NPJ Syst Biol Appl 4, 27 (2018); and Jenior, M. L. et al. Novel Drivers of Virulence in Clostridioides difficile Identified via Context-Specific Metabolic Network Analysis. mSystems 6, e0091921 (2021), the entire contents of all of three of which are incorporated by reference as if fully set forth herein. Additional details of GENRE’S as described herein can be found, for example, in Jenior, M. L., Leslie, J., Kolling, G. L., Archbald- Pannone, L., Powers, D., Petri, W. A., & 578 Papin, J. A. (2023). Systems-ecology designed bacterial consortium protects from severe Clostridioides difficile infection. bioRxiv, which is incorporated by reference as if fully set forth herein regarding methods of GENRE construction and GENREs utilized according to methods and systems of the present disclosure.
[0102] Methods as described herein can comprise identifying one or more bacterial species for administration from the determined taxonomic composition having cooperative or competitive metabolism with the candidate bacterial infection.
[0103] In embodiments of methods as described herein, the one or more metabolic pathways are one or more of amino acid biosynthesis, combined galactose metabolism, amino sugar metabolism, nucleotide sugar metabolism, starch metabolism, or sucrose metabolism, individually or in any combination thereof.
[0104] Referring next to FIG. 7, shown is a flowchart that provides one example of the operation of aspects of methods as described herein, method 100. The flowchart of FIG. 7 provides merely an example of the many different types of functional arrangements that can be employed to implement the operation of the depicted portion of methods described herein. As an alternative, the flowchart of FIG. 7 can be viewed as depicting an example of elements of a method implemented within a local system or a network environment as discussed herein.
[0105] Beginning with block 101 , the taxonomic microbiota composition is determined. This can be accomplished, for example, by determining, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determining, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; and optionally determining, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control.
[0106] Next, with block 103, the superorganism-level functional metabolic capacity is determined. This can involve, for example, determining superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data.
[0107] In block 105, metabolic pathways with differential metabolic capacity are identified. This can involve, for example, identifying metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities.
[0108] In block 107, the samples are clustered according to differential metabolic capacities. This can involve, for example, clustering the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities.
[0109] In block 109, genes are annotated, quantified, and segregated based on disease status. This can involve, for example, annotating the gene content of each cluster; quantifying the annotated gene content; and segregating the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status.
[0110] In block 111 , metabolism of the gene content is reconstructed. This can involve, for example, identifying genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples, and reconstructing the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition.
[0111] In block 113, the reconstructed metabolism is segregated. For example, the reconstructed metabolism of the determined taxonomic composition is segregated into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species.
[0112] In block 115, types of secondary bacterial species are identified in relation to a primary species. This can involve, for example, identifying the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species.
[0113] The flowcharts] and sequence diagrams show the functionality and operation of an implementation of portions of the various embodiments of the present disclosure. If embodied in software, each block can represent a module, segment, or portion of code that includes program instructions to implement the specified logical function(s). The program instructions can be embodied in the form of source code that includes human-readable statements written in a programming language or machine code that includes numerical instructions recognizable by a suitable execution system such as a processor in a computer system. The machine code can be converted from the source code through various processes. For example, the machine code can be generated from the source code with a compiler prior to execution of the corresponding application. As another example, the machine code can be generated from the source code concurrently with execution with an interpreter. Other approaches can also be used. If embodied in hardware, each block can represent a circuit or a number of interconnected circuits to implement the specified logical function or functions.
[0114] Although the flowcharts and sequence diagrams show a specific order of execution, it is understood that the order of execution can differ from that which is depicted. For example, the order of execution of two or more blocks can be scrambled relative to the order shown. Also, two or more blocks shown in succession can be executed concurrently or with partial concurrence. Further, in some embodiments, one or more of the blocks shown in the flowcharts and sequence diagrams can be skipped or omitted. In addition, any number of counters, state variables, warning semaphores, or messages might be added to the logical flow described herein, for purposes of enhanced utility, accounting, performance measurement, or providing troubleshooting aids, etc. It is understood that all such variations are within the scope of the present disclosure.
[0115] B. Systems for Predictive Platforms
[0116] FIG. 6 is a block diagram illustrating an example of a machine or system upon which one or more aspects of embodiments of the present invention can be implemented (in particular, systems and machine-readable media that can perform the methods in (A) above).
[0117] Referring to FIG. 6, an aspect of an embodiment of the present invention includes, but not limited thereto, system, method and computer readable medium for, among other things, one or more of the following: a) generating in silico predictions of BY-associated bacterial metabolic interactions via genome-scale metabolic network reconstructions (GENREs), b) identifying potential targets for therapeutic interventions by investigating the competitive and mutualistic relationships among BV-associated bacteria, c) computational modeling to simulate thousands of pairwise interactions between bacterial species to analyze possible competitive and mutualistic behaviors, and d) utilizing mutualistic and competitive interactions between bacterial pairs, to identify the intricate microbial community associated with BV, thereby developing more effective treatments for this prevalent condition. A block diagram of an example machine 400 upon which one or more embodiments (e.g., discussed methodologies) can be implemented (e.g., run) is shown in FIG. 6. Such systems described herein can be utilized to run any of the methods described herein, in particular, those embodied by the examples and as described in the methodologies above.
[0118] Examples of a machine 400 can include logic, one or more components, circuits (e.g., modules), or mechanisms. Circuits are tangible entities configured to perform certain operations. In an example, circuits can be arranged (e.g., internally or with respect to external entities such as other circuits) in a specified manner. In an example, one or more computer systems (e.g., a standalone, client or server computer system) or one or more hardware processors (processors) can be configured by software (e.g., instructions, an application portion, or an application) as a circuit that operates to perform certain operations as described herein. In an example, the software can reside (1) on a non-transitory machine readable medium or (2) in a transmission signal. In an example, the software, when executed by the underlying hardware of the circuit, causes the circuit to perform the certain operations.
[0119] In an example, a circuit can be implemented mechanically or electronically. For example, a circuit can comprise dedicated circuitry or logic that is specifically configured to perform one or more techniques such as discussed above, such as including a special-purpose processor, a field programmable gate array (FPGA) or an application-specific integrated circuit (ASIC). In an example, a circuit can comprise programmable logic (e.g., circuitry, as encompassed within a general-purpose processor or other programmable processor) that can be temporarily configured (e.g., by software) to perform the certain operations. It will be appreciated that the decision to implement a circuit mechanically (e.g., in dedicated and permanently configured circuitry), or in temporarily configured circuitry (e.g., configured by software) can be driven by cost and time considerations.
[0120] Accordingly, the term "circuit" is understood to encompass a tangible entity, be that an entity that is physically constructed, permanently configured (e.g., hardwired), or temporarily (e.g., transitorily) configured (e.g., programmed) to operate in a specified manner or to perform specified operations. In an example, given a plurality of temporarily configured circuits, each of the circuits need not be configured or instantiated at any one instance in time. For example, where the circuits comprise a general-purpose processor configured via software, the general- purpose processor can be configured as respective different circuits at different times. Software can accordingly configure a processor, for example, to constitute a particular circuit at one instance of time and to constitute a different circuit at a different instance of time.
[0121] In an example, circuits can provide information to, and receive information from, other circuits. In this example, the circuits can be regarded as being communicatively coupled to one or more other circuits. Where multiple of such circuits exist contemporaneously, communications can be achieved through signal transmission (e.g., over appropriate circuits and buses) that connect the circuits. In embodiments in which multiple circuits are configured or instantiated at different times, communications between suet, circuits can be achieved, for example, through the storage and retrieval of information in memory structures to which the multiple circuits have access. For example, one circuit can perform an operation and store the output of that operation in a memory device to which it is communicatively coupled. A further circuit can then, at a later time, access the memory device to retrieve and process the stored output. In an example, circuits can be configured to initiate or receive communications with input or output devices and can operate on a resource (e.g., a collection of information).
[0122] The various operations of method examples described herein can be performed, at least partially, by one or more processors that are temporarily configured (e.g., by software) or permanently configured to perform the relevant operations. Whether temporarily or permanently configured, such processors can constitute processor-implemented circuits that operate to perform one or more operations or functions. In an example, the circuits referred to herein can comprise processor-implemented circuits.
[0123] Similarly, the methods described herein can be at least partially processor-implemented. For example, at least some of the operations of a method can be performed by one or processors or processor-implemented circuits. The performance of certain of the operations can be distributed among the one or more processors, not only residing within a single machine, but deployed across a number of machines. In an example, the processor or processors can be located in a single location (e.g., wittl in a tlome environment, an office environment or as a server farm), while in other examples the processors can be distributed across a number of locations.
[0124] The one or more processors can also operate to support performance of the relevant operations in a "cloud computing" environment or as a "software as a service" (SaaS). For example, at least some of the operations can be performed by a group of computers (as examples of machines including processors), with these operations being accessible via a network (e.g., the Internet) and via one or more appropriate interfaces (e.g., Application Program Interfaces (APIs).)
[0125] Example embodiments (e.g., apparatus, systems, or methods) can be implemented in digital electronic circuitry, in computer hardware, in firmware, in software, or in any combination thereof. Example embodiments can be implemented using a computer program product (e.g., a computer program, tangibly embodied in an information carrier or in a machine readable medium, for execution by, or to control the operation of, data processing apparatus such as a programmable processor, a computer, or multiple computers).
[0126] A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a standalone program or as a software module, subroutine, or other unit suitable for use in a computing environment. A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a communication network.
[0127] In an example, operations can be performed by one or more programmable processors executing a computer program to perform functions by operating on input data and generating output. Examples of method operations can also be performed by, and example apparatus can be implemented as, special purpose logic circuitry (e.g., a field programmable gate array (FPGA) or an application-specific integrated circuit (ASIC)).
[0128] The computing system can include clients and servers. A client and server are generally remote from each other and generally interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other. In embodiments deploying a programmable computing system, it will be appreciated that both hardware and software architectures require consideration. Specifically, it will be appreciated that tt1 e choice of whether to implement certain functionality in permanently configured h ardware (e.g., an ASIC), in temporarily configured hardware (e.g., a combination of software and a programmable processor), or a combination of permanently and temporarily configured hardware can be a design choice. Below are set out hardware (e.g., machine 400) and software architectures that can be deployed in example embodiments.
[0129] In an example, the machine 400 can operate as a standalone device or the machine 400 can be connected (e.g., networked) to other machines.
[0130] In a networked deployment, the machine 400 can operate in the capacity of either a server or a client machine in server-client network environments. In an example, machine 400 can act as a peer mactl ine in peer-to-peer (or other distributed) network environments. The machine 400 can be a personal computer (PC), a tablet PC, a set-top box (STB), a Personal Digital Assistant (PDA), a mobile telephone, a web appliance, a network router, switch or bridge, or any machine capable of executing instructions (sequential or otherwise) specifying actions to be taken (e.g., performed) by the machine 400. Further, while only a single machine 400 is illustrated, the term "machine" shall also be taken to include any collection of machines that individually or jointly execute a set (or multiple sets) of instructions to perform any one or more of the methodologies discussed herein.
[0131] Example machine (e.g., computer system) 400 can include a processor 402 (e.g., a central processing unit (CPU), a graphics processing unit (GPU) or both), a main memory 404 and a static memory 406, some or all of which can communicate with each other via a bus 408. The machine 400 can further include a display unit 410, an alphanumeric input device 412 (e.g., a keyboard), and a user interface (Ul) navigation device 411 (e.g., a mouse). In an example, the display unit 810, input device 417 and Ul navigation device 414 can be a touch screen display. The mactl ine 400 can additionally include a storage device (e.g., drive unit) 416, a signal generation device 418 (e.g., a speaker), a network interface device 420, and one or more sensors 421 , such as a global positioning system (GPS) sensor, compass, accelerometer, or other sensor.
[0132] The storage device 416 can include a machine readable medium 422 on which is stored one or more sets of data structures or instructions 424 (e.g., software) embodying or utilized by any one or more of the methodologies or functions described herein. The instructions 424 can also reside, completely or at least partially, within the main memory 404, within static memory 406, or within the processor 402 during execution thereof by the machine 400. In an example, one or any combination of the processor 402, the main memory 404, the static memory 406, or the storage device 416 can constitute machine readable media.
[0133] While the machine readable medium 422 is illustrated as a single medium, the term "machine readable medium" can include a single medium or multiple media (e.g., a centralized or distributed database, and / or associated caches and servers) that configured to store the one or more instructions 424. The term "machine readable medium" can also be taken to include any tangible medium that is capable of storing, encoding, or carrying instructions for execution by the machine and that cause the machine to perform any one or more of the methodologies of the present disclosure orthat is capable of storing, encoding or carrying data structures utilized by or associated with such instructions. The term "machine readable medium" can accordingly be taken to include, but not be limited to, solid-state memories, and optical and magnetic media. Specific examples of mactl ine readable media can include nonvolatile memory, including, by way of example, semiconductor memory devices (e.g., Electrically Programmable Read-Only Memory (EPROM), Electrically Erasable Programmable Read-Only Memory (EEPROM)) and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.
[0134] The instructions 424 can further be transmitted or received over a communications network 426 using a transmission medium via the network interface device 420 utilizing any one of a number of transfer protocols (e.g., frame relay, IP, TCP, UDP, HTTP, etc.). Example communication networks can include a local area network (LAN), a wide area network (WAN), a packet data network (e.g., the Internet), mobile telephone networks (e.g., cellular networks), Plain Old Telephone (POTS) networks, and wireless data networks (e.g., IEEE 802.11 standards family known as Wi-Fi®, IEEE 802.16 standards family known as WiMax®), peer- to-peer (P2P) networks, among others. The term "transmission medium" shall be taken to include any intangible medium that is capable of storing, encoding or carrying instructions for execution by the machine, and includes digital or analog communications signals or other intangible medium to facilitate communication of such software.
[0135] II. MICROBIAL POPULATIONS
[0136] Samples comprising microbial compositions are analyzed according to methods and systems of the present disclosure. Samples as described herein can be biological samples taken from a subject that comprise one or more bacterial strains (also referred to as “microbiota”). In embodiments, the one or more bacterial strains can comprise bacteria (also referred to herein as “micro-organism” or “micro-organisms”) that can be grampositive, nonmotile, branched anaerobic bacteria. In embodiments, the one or more bacterial strains can comprise bacteria that can be gram-negative, facultative anaerobic, rod-shaped, coliform bacteria. In embodiments, the one or more bacterial strains can comprise bacteria that can be gram-positive anaerobic bacteria. In embodiments, the one or more bacterial strains can comprise bacteria that can be gram-positive and facultatively anaerobic. Bacteria consortia as described herein comprise viable and metabolically active micro-organisms, which can be proliferative or non-proliferative.
[0137] Samples according to the present disclosure, in certain aspects, may be enriched in L. iners, P. amnii, P. buccalis, H. timonensis, F. vaginae, A. christensii, G. vaginalis, and G. piotii, thereby containing these strains at a higher level than other strains. Samples as described herein may, as a primary bacterial candidate, comprise Gardnerella species, as well as others as described herein.
[0138] While embodiments of the present disclosure are described in connection with the Examples and the corresponding text and figures, there is no intent to limit the disclosure to the embodiments in these descriptions. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.
[0139] Other features, objects, and advantages of the present invention are apparent in the description that follows. It should be understood, however, that the description, while exemplifying certain embodiments of the present invention, is given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.
[0140] III. EXAMPLES
[0141] Now having described the embodiments of the disclosure, in general, the examples describe some additional embodiments. While embodiments of the present disclosure are described in connection with the example and the corresponding text and figures, there is no intent to limit embodiments of the disclosure to these descriptions. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.
[0142] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the compositions and compounds disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C, and pressure is in atmosphere. Standard temperature and pressure are defined as 25 °C and 1 atmosphere.
[0143] EXAMPLE 1 :
[0144] A. Introduction
[0145] Bacterial vaginosis (BV) is the most common state of vaginal dysbiosis among reproductive age women with vaginal complaints (Schwiertz et al., 2006). BV is a polymicrobial condition characterized by low levels of Lactobacillus, high levels of diverse anaerobes, a vaginal pH greater than 4.5, thin vaginal discharge, and a fishy odor (Wang, 2000). Various factors, such as sexual activity, menstruation, antibiotics, and douching can alter a healthy, acidic, Lactobacillus-dominant, vaginal microbiome, and lead to the development of BV (Gajer et al., 2012; Lopes dos Santos Santiago et al., 2012; Mayer et al., 2015; Tachedjian et al., 2017; Tortelli et al., 2020). BV is disproportionally prevalent among women of color, affecting 33-64% of Black women, and 31-32% of Hispanic women, compared to 23-35% of White women (Allsworth et al., 2008; Culhane et al., 2002; Koumans et al., 2007, p. 20; Muzny & Kardas, 2020). BV increases risk of contracting sexually transmitted diseases, including HIV, and is also associated with risk of preterm birth (Feehily et al., 2020; Fettweis et al., 2019; Shimaoka et al., 2019). BV accounts for an estimated cost of $14.4 billion USD annually when considering both BV treatment costs and BV-associated healthcare costs in the United States alone (Peebles et al., 2019).
[0146] Despite the significant impact of BV on women's health, there is a dearth of information regarding the microbial community structure and metabolic interactions associated with this condition (Bradshaw & Sobel, 2016). By investigating the competitive and mutualistic relationships among BV-associated bacteria, potential targets for therapeutic interventions can be identified. The inclusive list of bacteria involved in BV has yet to be defined; however, certain bacterial species are commonly associated with this condition, including: Gardnerella species, Prevotella bivia, Prevotella amnii, Prevotella buccalis, Hoylesella timonensis, Lactobacillus iners, Fannyhessea vaginae, and Aerrococcus christenssii (FIG. 1) (Forsum et al., 2005; Marrazzo et al., 2009, 2009; Srinivasan et al., 2012). Although the Gardnerella genus is the primary contributor to BV, the large number of distinct Gardnerella species associated with BV make experimental analysis challenging (Castro et al., 2019; Dillard et al., 2022; Horrocks et al., n.d.; Janulaitiene et al., 2017). Computational modeling allows for the simulation of thousands of pairwise interactions between bacterial species to analyze possible competitive and mutualistic behaviors.
[0147] In the present examples, an analysis of metagenomic data obtained from human vaginal swabs was undertaken in order to ascertain the microbial composition of both symptomatic and asymptomatic cases of BV. With these data, in silico predictions of BV- associated bacterial metabolic interactions were generated using genome-scale metabolic network reconstructions (GENREs). To validate these predictions, in vitro growth experiments were carried out. Furthermore, bacterial supernatants were collected and analyzed to identify metabolites that putatively underlie BV-associated bacterial interactions. Follow-up experiments were then conducted to confirm the role of metabolites that were implicated both in silico and in vitro in contributing to competitive interactions. By elucidating the underlying mutualistic and competitive interactions between bacterial pairs, we enhance our understanding of the intricate microbial community associated with BV, ultimately leading to the development of more rigorous typing of BV and possible effective treatments for this prevalent condition. B. Results
[0148] BV Symptom Status Shapes Distinct in vivo Co-Occurrence Paterns Among Bacterial Species
[0149] L. iners, G. vaginalis, F. vaginae, and H. timonensis are frequently found to co-occur in both symptomatic and asymptomatic samples of BV (FIG. 1). L. iners was observed to cooccur with G. vaginalis in 33% of healthy samples, whereas the co-occurrence of F. vaginae and H. timonensis was only 5% and 8%, respectively. A. christensenii and P. bivia were identified as more common co-occurring species in symptomatic samples. On the other hand, P. amnii, P. buccalis, and H. timonensis were more commonly observed as co-occurring species with G. vaginalis in asymptomatic samples. Demographic features collected from sample metadata did not appear to correlate with differences in symptomatic, asymptomatic and healthy samples (Table 1 below).
[0150] Table 1 : Demographics and clinical characteristics of vaginal metagenomic samples
[0151] Average nucleotide identity (ANI) of Gardnerella genomes identified 13 genetically distinct species, all of which have been previously characterized, and are defined here as 95% genetic similarity (S1). Four species are already named (G. vaginalis, G. piotii, G. swidsinkii, and G. leopoldii) with the remainder unnamed and therefore given a number (species 1-9). Within these species there were also distinct genetic clades for both G. vaginalis and G. piotii designated as clades A and B in each (S1). EXAMPLE 2: There are Complex Mutualistic and Competitive Relationships
[0152] Between BV Bacteria
[0153] Mutualism, competition, and net (sum of positive mutualism flux with negative competition flux) interactions were examined at the single bacterial species, single interaction level. In the context of these in silico simulations, primary bacteria are the focal bacterial species whose biomass flux changes are measured and analyzed. Co-occurring bacteria are those that interact with the primary bacteria within the simulation environment. Their presence influences the biomass flux of the primary bacteria through competitive or mutualistic interactions, thereby affecting the primary bacteria’s metabolic dynamics and overall community structure. Through our high-throughput pairwise simulations, each bacterial species serves as both the primary and co-occurring bacteria at different points. This means that for each interaction pair, two outputs are generated: (1) one where bacteria 1 is the primary and bacteria 2 is co-occurring, and (2) one where bacteria 1 is co-occurring and bacteria 2 is primary. The investigation revealed a consistent lack of mutualism benefit across two Prevotella species and H. timonensis, which cluster closely at the primary bacteria level (FIG. 2A). In contrast, A. christensii and L. iners showed significant mutualistic benefits in pairwise simulations. In terms of competition, a small subset of Gardnerella strains at the bottom-most of the heatmap were repeatedly outcompeted, as evidenced by high biomass flux decrease across almost all interactions (FIG. 2B). At the net flux level, iners and A. christensii at the primary bacteria level flux values indicated consistent biomass benefit from mutualistic interactions and low biomass cost due to competition (FIG. 2C). Finally, L. iners, all Prevotella species, H. timonensis, F. vaginae, A. christensii, and some Gardnerella strains played significant mutualistic roles in approximately half of the primary bacterial strain interactions, while playing a more neutral to competitive role in the other half of primary bacterial strain interactions.
[0154] Single bacterial species were assessed across interactions - mutualistic, competitive, and net - to examine high-level patterns of bacterial similarity. \r\ter-Gardnerella clade clustering was found during mutualism, including G. leopoldii, G. swidsinksii, G. 1,2, 3, 4, and unknown strains (FIG. 2D). Additionally, clustering across G. vaginalis, G. piotii, G. 5, 6, 7, 8, 9, and P. amnii was observed. Specifically, P. amnii clustered independently from P. bivia and P. buccalis. Conversely, there was less prevalent local structure observed at the competition level including clustering of A. christensenii, G. piotii, G. vaginalis, G. 1,2, 3, 4, G. 5, 6, 7, 8,9, P. bivia and an unknown Gardnerella (FIG. 2E). Looking at net flux values, analogous inter- Gardnerella clustering of species clustered in mutualisms is observed (FIG. 2F).
[0155] Based on the analysis of average mutualism benefit and average competition cost as quantified via change in flux through biomass, it was found that L. iners and A. christensenii both significantly benefited from pairwise mutualism compared to low competition cost (FIG. 3A). Conversely, H. timonensis showed high competition cost relative to its low mutualism benefit. The analyses showed that most of the investigated strains fell within the low to medium mutualism benefit range, with a similarly low to medium competition cost, except for one Gardnerella strain with significant competition cost.
[0156] Using a one-tailed t-test, followed by Bonferroni multiple test corrections, secondary bacteria were highlighted that most significantly benefited primary bacteria with which they cooccurred. The top five most mutualistic bacteria belonged to the following Gardnerella clades: G. 8 (p-value: 2.18 x 10 ", t-statistic: 42.6), unknown strain (p-value: 4.59 x 10 ", t-statistic: 39.2), G. piotii B (p-value: 7.12 x 1085, t-statistic: 35.2), G. leopoldii (p-value: 3.50 x 1084, t- statistic: 34.8), and G. 5 (p-value: 4.31 x 10’80, t-statistic: 32.9). Conversely, the top bacterial competitors were defined as secondary bacteria that most significantly outcompeted primary bacteria, resulting in a decrease in biomass during pairwise simulations. The top five most competitive bacteria fell under the following Gardnerella clades: G. 8 (p-value: 4.82 x 1051, t- statistic: 21.3), unknown species (p-value: 3.77 x 1044, 18.9), G. 9 (p-value: 1.57 x 1043, t- statistic: 18.7). G. 3 (p-value: 1.74 x 10'43, t-statistic: 18.7), and G. 7 (p-value: 1.74 x 10-43, t- statistic: 18.7). The most competitive and most mutualistic bacteria were overlaid onto the Gardnerella ANI dendrogram and a greater genetic diversity was observed among top mutualistic bacteria compared to the top competitive bacterial strains (FIG. 3B).
[0157] The analysis of the most commonly shared and / or competed for metabolites highlighted the physiological relevance of four metabolites in the BV-positive in silico bacterial interaction simulation (FIG. 3C). Specifically, L-histidine (Competitive interactions: 98%; Mutualistic interactions: 94%), which can be decarboxylated to form histamine, a key host inflammatory response immune regulator (Branco et al., 2018). Selenocysteine (Competitive interactions: 94%), is an essential component of selenoproteins, which play a role in host immune function (Avery & Hoffmann, 2018; Rayman, 2000). Sphinganine 1 -phosphate (S1 P) (Competitive interactions: 35%) has been associated with pro-inflammatory properties and implicated in tissue damage, but rarely implicated in bacterial metabolism (Ledgerwood et al., 2008; Liu et al., 2021). Iron (III) (Competitive interactions: 78%; Mutualistic interactions: 75%) is an essential Gardnerella growth micronutrient (Jarosik et al., 1998). The relationship between L-histidine and G. piotii growth was then directly probed. G. piotii had a 41 .3% growth benefit when grown in NYCIII enriched with 0.1 % L-histidine compared to NYCIII enriched media alone, as confirmed by a one-tailed t-test (t=3.49, p-value = 0.002) (FIG. 3D).
[0158] EXAMPLE 3: Experimental Validation Highlights Metabolic Interactions That Drive BV Microbial Dynamics
[0159] Growth Curves
[0160] Because of the fastidious nature of P. bivia, it was not used for in vitro analysis. P. amnii, F. vaginae, and H. timonensis all showed similar growth capacity in NYCIII enriched media compared to G. piotii spent media (FIGs. 4A-4C). L. iners and G. vaginalis had 44% and 37% reduced growth in G. piotii spent media compared to enriched media (Fig 4D-E)). All species had minimal growth in G. vaginalis spent media. G. piotii, A. christensii, and P. buccalis had minimal growth across all three conditions (Fig 4F-H).
[0161] Metabolomics
[0162] Both P. amnii and G. piotii showed no growth in G. vaginalis spent media and were not submitted for metabolomics analysis. After filtering for p-value and log2(fold change) (<0.01 , > |2|) 85 metabolites were identified as significantly consumed and 87 metabolites were identified as significantly produced (Table 2 below). Using ORA the top three metabolite super-classes were identified that were most significantly enriched in both consumed and produced metabolites based on enrichment ratio. Consumed metabolites were enriched for nucleic acids (Enrichment-ratio: 272.7; Holm p-value: 1.95 x 1012), carbohydrates, (Enrichment-ratio: 182.9; Holm p-value: 1.57 x 105), and organic acids, (Enrichment-ratio: 54.5; Holm p-value: 3.05 x 108). Produced metabolites were enriched for nucleic acids (Enrichment-ratio: 263.2; Holm p-value: 2.0 x 10‘14), carbohydrates (Enrichment-ratio: 100.5; Holm p-value: 0.004), and organoheterocyclic compounds (Enrichment-ratio: 58.4; Holm p- value: 1.74 x 10‘5).
[0163] Table 2: Metabolites identified as significantly consumed or produced based on spent media metabolomics (p-value <0.01 ; Iog2(fold change)>|2|)
[0164] G. piotii significantly consumed L-histidine when grown in fresh media (FIG. 5A). Both G. vaginalis and G. piotii produced protocatechuic acid (PCA) and 2-hydroxyisobutryic acid (2-HIBA) (FIGs. 5A-5B). PCA has been shown to have beneficial anti-inflammatory effects in the gut (Murota et al., 2018). Conversely previous research has identified 2-HIBA as a disease biomarker for diabetes, adiposity, as well as autoimmune diseases (Elliott et al., 2015; Li et al., 2009; Tsoukalas et al., 2020). Both G. vaginalis and H. timonensis significantly consumed the volatile fatty acid, propionic acid, which has been found to be elevated in BV positive cervicovaginal fluid (FIGs. 5B-5C) (Al-Mushrif et al., 2000; Delgado-Diaz et al., 2020; Gajer et al., 2012; Mirmonsef et al., 2011 ; Spiegel et al., 1983). The relationship between propionic acid and H. timonensis growth was directed investigated. H. timonensis had a minimal growth benefit when grown in NYCIII enriched with 0.01 % propionic acid compared to NYCIII enriched media alone (S2A). F. vaginae grown in G. vaginalis spent media did not have any significantly different metabolites. L iners significantly produced lactic acid only when grown in G. piotii spent media (FIG. 5D). Caffeate is specifically produced by F. vaginae when grown in G. piotii compared to NYCIII enriched media (p-value = 0.07) (FIG. 5E-F). Caffeate is able to bind to estrogen receptor alpha (ERa), which is located throughout the vaginal tissue (Rezaei-Seresht et al., 2019). Other differentially produced or consumed metabolites were found, but their physiological relevance was not explored further (Fig S2 B-l).
[0165] EXAMPLE 4: Further Discussion of Examples 1-3
[0166] Despite the significant impact of BV on both acute and chronic health, there is a lack of understanding regarding the microbial community structures and metabolic interactions underlying this condition. The present examples utilize clinical data, in silico, and in vitro analyses to investigate the variations in Gardnerella co-occurring species between symptomatic and asymptomatic BV, as well as explore the differential interactions of Gardnerella strains with each other and non- Gardnerella co-occurring species. By using spent media, how bacterial growth is influenced by the metabolic byproducts and nutrient depletion caused by other bacteria can be evaluated, providing a more realistic insight into inter-bacterial dynamics. Additionally, in silico predictions were compared with in vitro metabolomics of spent media to further understand the metabolites defining inter-bacterial interactions.
[0167] Using in vivo metagenomic analysis of vaginal swabs, variations in BV community structure were observed between symptomatic and asymptomatic samples. These findings indicate a higher prevalence of A. christensii and P. bivia in symptomatic samples, while P. amnii, P. buccalis, and H. timonensis were more frequently found in asymptomatic samples. These differences in community structures underscore the need for further sub-categorization of BV. By establishing more specific definitions, development of more targeted treatments that move away from the current broad-spectrum antibiotic approach are possible (Kedaigle & Fraenkel, 2018; Sun et al., 2014; Zhang et al., 2022).
[0168] The complexity of BV is further supported by in silico simulations of pair-wise bacterial interactions. GENREs are a powerful tool for predicting metabolic interactions because they allow for the simulation of complex biological systems and the identification of potential metabolic pathways and interactions. By providing a framework to analyze thousands of pair- wise interactions, GENREs help uncover the metabolic dynamics that are not immediately apparent through experimental methods alone. The analysis of the examples herein reveal significant clustering between Gardnerella species based on assessed mutualistic benefit, indicating that genetic similarity does not necessarily correlate with functional metabolic similarities. Additionally, a bifurcated metabolic benefit is obversed versus metabolic cost of L. iners, all Prevotella species, H. timonensis, F. vaginae, A. christensii, and certain Gardnerella strains when co-occurring with Gardnerella strains. This result suggests that a strain's metabolic relationship may be beneficial in one inter-bacterial context but detrimental in another. Overall, A. christensii and L. iners appear to consistently benefit the most from inter-bacterial interactions in silico. Experiments reveal that A. christensii does not experience growth benefits when cultured in spent media of either G. vaginalis or G. piotii. These findings differ from in silico predictions and demonstrate that pair-wise simulations cannot fully capture the complexity of the polymicrobial communities present in BV.
[0169] Exactly what specific metabolites were being consumed and produced by co-occurring species in BV were examined. G. piotii significantly consumed L-histidine both in metabolomics analyses and growth curve analyses, which recapitulated an in silico prediction that L-histidine is highly competed over. Metabolomics analysis was also able to reveal metabolite production and consumption that was not demonstrated in the in silico analysis. Specifically, F. vaginae significantly produced caffeate when grown in G. piotii spent media, which we confirmed is specific to a BV metabolic context and is not ubiquitously produced. Previous studies have shown that caffeate can bind to ERa, which regulates estrogen sensitive gene expression. Reduced circulating estrogen levels results in vaginal epithelial atrophy, as seen in post-menopausal women (Jelinsky et al., 2008). These findings point to the importance of ERa in supporting vaginal epithelial health. Conversely, previous research has demonstrated estrogen-dependent focal adhesion kinase (FAK) activation in vaginal epithelial cell tissue (Sanchez et al., 2011). The mechanism of action centers on estrogen binding to ERa, precipitating ERa phosphorylation, which cascades to FAK phosphorylation. Additionally, it was found that estrogen dependent FAK activation precipitates increased bacterial adhesion on the vaginal epithelium (Liu et al., 2021). Lastly, previous research has shown BV-associated metabolites can alter vaginal immune response (Eade et al., 2012; Fichorova et al., 2013). These data, in combination with the data herein, indicate that BV- specific metabolic byproducts may alter vaginal epithelial regulation.
[0170] In summary, the present examples shed light on the varied community composition and metabolic interactions associated with BV, a prevalent vaginal condition that significantly impacts women's health. By analyzing vaginal metagenomic data and constructing pair-wise metabolic network simulations of BV-associated bacteria, the context dependent nature of these competitive and mutualistic relationships has been highlighted. Through metabolomics analysis, the role of specific metabolites in these inter-bacterial interactions was further investigated. The findings further emphasize the complex and diverse nature of BV-associated bacterial community structures. EXAMPLE 5: Materials and Methods for Examples 1-3
[0171] Gardnerella and co-occurring species comparison
[0172] Sample Collection
[0173] Analysis of vaginal organism co-occurrence was generated using data from participants on the Evvy platform (IRB# 20220118. ewy). Sample collection, processing, shotgun metagenomic sequencing (NovaSeq, Illumina), and bioinformatics analysis was completed as described previously (Thomas-White 2024). Samples were selected based on self-reported symptom profile. Gandne / 'eZ / a-dominant profiles were selected and then stratified by either asymptomatic or symptomatic, defined as the presence of self-reported excessive discharge and vulvovaginal pruritus.
[0174] Co-occurrence Frequency
[0175] Samples were split into three different groups: symptomatic BV (N=212), asymptomatic BV (N=504) and a healthy cohort (N=154) (Table 1). The symptomatic and asymptomatic BV groups both consisted of samples of Community State Type (CST) 4 and were dominated by Gardnerella (>= 50% relative abundance) (De Seta et al., 2019). However, the symptomatic BV group experienced excessive discharge and itchiness (either internal or external), while these symptoms were absent in the asymptomatic BV group. The healthy cohort consisted of samples of CST 1 , 2 or 5, dominated by lactobacilli, with a relative abundance of >= 50% L. crispatus, L. gasseri, L. paragasseri, L. pensenii, L. mulieris and did not experience excessive discharge nor itchiness. Relative frequency of species that co-occur with Gardnerella vaginalis within each subgroup was calculated using the following formula:
[0176] # of samples with >= 2% relative abundance of co-occurring species
[0177] # of samples with >= 2 % relative abundance of G. vaginalis
[0178] Average nucleotide identity for speciation determination
[0179] The nucleotide similarity between the Gardnerella genomes was determined using ANI comparison (Goris et al., 2007). 222 Gardnerella genomes were input to pyani (vO.2.12), a Python implementation tool for ANI analysis (Pritchard et al., 2015). After running an initial comparison with pyani using the ANIb method, 13 genomes were removed from the analysis as they were too divergent from the majority of genomes. The remaining 209 Gardnerella genomes were input to pyani and the ANIb method which aligns 1020 nt fragments of the input sequences using BLASTN+ was used (Madden, 2002; Madden & Camacho, 2021). The generated percentage identity heatmap was color coded based on the taxonomic classifications given by the NCBI records of the genomes (Schoch et al., 2020).
[0180] Dendrogram construction
[0181] The pyani analysis generated a distance matrix for percentage identity, which was used to generate a dendrogram. The distance matrix was clustered via hierarchical clustering using the “complete” method via the TAPE R package (v0.3.0) (Zhuang et al., 2022). The clustered output was then converted to a tree object in Newick tree format. The dendrogram tree file was visualized using iTOL v6.7.1 and color coded based on the taxonomic classifications of the genomes’ NCBI records (Letunic & Bork, 2021).
[0182] Model construction and contextualization
[0183] We analyzed potential metabolic interactions among Gardnerella strains by identifying 208 Gardnerella whole genome sequences from the BV-BRC 3.28.21 database that meet the "good" quality criteria defined as a genome with at least 80% completeness, less than 10% contamination, and at least 87% consistency with known protein sequences (Olson et al., 2023). Thirteen genomes were removed due to ANI clustering indicating either incomplete genome sequence or chimera status. We used the remaining 195 Gardnerella strains' annotated amino acid sequences to generate GENRES using the Reconstructor (v1.1.0) algorithm (Jenior et al., 2023). Additionally, we created GENREs for seven co-occurring species of interest: Lactobacillus iners, Prevotella bivia, Prevotella amnii, Prevotella buccalis, Hoylesella timonensis, Fannyhessea vaginae, and Aerococcus christensii. The quality of the GENREs was assessed using MEMOTE (v0.13.0), which is the standard metric in computational metabolic modeling (Lieven et al., 2020). The GENREs and corresponding MEMOTE scores are available at the project's GitHub repository, which is incorporated by reference in its entirety as if fully set forth herein. (https: / / qithub.com / emmamqlass / Gardnerella-lnteractions).
[0184] After constructing the GENREs, we created a list of minimal metabolites required for 20% of maximal biomass production (Min20) for each individual GENRE using the COBRApy toolbox (v3.0) minimal_medium built-in function. We combined those minimal metabolite requirement lists to form a consensus list of minimal metabolites across all GENREs (Min20). To simulate vaginal dysbiosis, we also composed an in silico BVpositive cervicovaginal fluid media (BV-CFM) based on previous metabolomics analysis of cervicovaginal fluid collected from both healthy and BV-positive patients (Vitali et al., 2015). This BV-CFM in silico media was enriched for metabolites found to be significantly elevated in BV-positive cervicovaginal fluid. We added transport reactions, which were absent from initial model construction but required for in silico media metabolite usage, in addition to respective exchange reactions. The final in silico media used for model simulation consisted of Min20 + BV-CFM.
[0185] Competition and mutualism simulation
[0186] To analyze the metabolic interactions between Gardnerella strains and other cooccurring species, we used a metabolic interaction prediction algorithm developed previously and applied it to the 202 GENREs that we constructed (Jenior et al., 2023). This method allowed us to simulate approximately 20,000 pairwise interactions and calculate the impact on biomass production and extracellular metabolites. We used a heatmap generated in R’s pheatmap package (v1.0.12) to visualize the increase or decrease in biomass flux due to mutualism or competition, respectively (Kolde, 2019). Columns and rows were hierarchically clustered using the built-in Ward’s minimum variance method, and associated distance matrix using the built-in Euclidean distance method (Lele & Richtsmeier, 1995; Ward, 1963). We also calculated net-flux values and visualized them using the same methodology.
[0187] To better understand the clustering of strains based on mutualistic benefit, competitive cost, and net outcome, we used T-distributed Stochastic Neighbor Embedding (t-SNE) for dimensionality reduction and visualization (Van der Maaten & Hinton, 2008). We generated three plots via the R Rtsne package (v0.17) using mutualism biomass flux increase values, competition biomass flux decrease values, and net-flux values, respectively (iteration = 50,000; perplexity = 14) (Van der Maaten & Hinton, 2008). ANI-calculated clading values were used to color Gardnerella data points and highlight strain level inter-clade clustering.
[0188] To understand the relationship between mutualistic benefit and competition cost, we calculated the average decrease in biomass flux due to competition and the average increase in biomass flux due to mutualism for each bacterial strain. We then graphed all 202 bacteria of interest as depicted in FIGs. 2A-2F. We identified the top five most competitive and most mutualistic bacteria using a one-tailed t-test and corresponding Bonferroni multiple test correction using the p. adjust R function from Rstats package (v3.6.2) (Bonferroni, 1936; Student, 1908). Finally, we calculated the percent of total interactions a metabolite was either competed for and / or shared between GENREs.
[0189] Spent Media Analysis
[0190] Metabolomics sample collection
[0191] The following describes the experimental setup and sample preparation for metabolomics analysis of Gardnerella vaginalis (strain ATCC 14018) and Gardnerella piotii (strain JCP8151 B) primary spent media. The bacteria were grown overnight under anaerobic conditions in NYCIII + 2% FBS media, and inoculated into T25 polystyrene tissue culture flasks. After 18 hours of incubation, samples were collected from each flask, spun down (15 minutes; 7,500 RPM), and filter-sterilized (0.2p filter). The filtered supernatant was stored at - 80°C until metabolomics processing. ODeoowas recorded prior to the spin down step. Pooled spent media samples for both G. vaginalis and G. piotii were also aliquoted into microcentrifuge tubes and stored at -80°C. The remaining spent media for G. vaginalis and G. piotii was stored at -20°C.
[0192] In order to collect metabolomics on spent media conditions, six of the co-occurring species - L. iners, P. amnii, P. buccalis, H. timonensis, F. vaginae and A. christensii - were grown overnight in enriched media (NYCIII+2% FBS, BHI, or MRS) under anaerobic conditions. Twelve-well plates with 2.5 mL of either G. piotii or G. vaginalis spent media were inoculated with 100 pL of co-occurring species inoculum. After inoculation, samples were grown to saturation and OD60Q measured. Samples were then collected from each flask, spun down (5 minutes; 5,000 RPM), filter-sterilized and stored at -80°C.
[0193] Mass spectrometry sample preparation and analysis
[0194] Untargeted metabolomics was performed by the University of Virginia Biomolecular Analysis Facility Core. Sample preparation involved adding 2000 pL of 80% methanol (-20 °C) to 500 pL of each culture medium. The mixture was vortexed for one minute and incubated at -20 °C for two hours to induce protein precipitation. Subsequently, the tubes were centrifuged at 14,000 g for 30 minutes at 4 °C. The resulting supernatants were transferred to new tubes, and a quality control (QC) sample was prepared by combining 35 pL from each sample. All samples were then dried in a speed vacuum for approximately four hours and stored at -80 °C until further processing. There were N=5 replicates for each mass spec sample, which were pulled from 5 distinct samples.
[0195] For mass spectrometry analysis, the dried samples were reconstituted in 100 pL of 0.1 % formic acid along with 100X diluted Metabolomics QReSS heavy-labeled standards (Percy et al., 2022; Percy, Andrew et al., 2021). A dilution of 1 :800 was applied to both samples and QC sample. Subsequently, 10 pL of each diluted sample was injected for analysis.
[0196] Mass spectrometry data acquisition was performed using a Thermo Orbitrap IDX MS connected to a Vanquish UPLC system. A Waters BEH C18 column (100 x 2.1 mm, 1.9 pm) was employed for soluble metabolite separation. The column temperature was set at 30 °C, and a flow rate of 250 pL / min was maintained. The mobile phase consisted of 0.1% formic acid in water (mobile phase A) and 0.1 % formic acid in methanol (mobile phase B). The mass scan range was set from 67 to 1000 with a resolution of 120,000 and a scan range of 0.6 sec.
[0197] Data-dependent MS2 scans were obtained using a real-time precursor exclusion strategy with AcquireX mode. Prior to the analysis of the samples, initial runs were performed with solvent blank samples in full scan mode (67-1000 mass range) to generate an exclusion list containing all the peaks present in the blank samples. A QC sample was then run in full scan mode, and all the peaks were saved as an inclusion list. Four data-dependent acquisition (DDA) injections were performed, with the exclusion list automatically updated based on the selected precursor.
[0198] After data acquisition, the samples were subjected to analysis using the open-source software MS-DIAL (Tsugawa et al., 2015, 2019). To identify and remove background ions, five blank samples were included in the analysis. The samples acquired in full scan MS1 mode were used for quantification, while the samples acquired in DDA mode were utilized for spectral identification of metabolites. The MS1 tolerance was set to 0.01 Da, and the MS2 tolerance was set to 0.025 Da. For peak picking, a mass slice width of 0.1 was employed. Peak alignment was performed with a maximum retention time tolerance of 0.2 min and an MS1 tolerance of 0.015.
[0199] Peak identification was carried out by searching the MS2 spectra against the MS-DIAL public database (January 2023). A mass tolerance of 0.01 Da for MS1 and 0.05 Da for MSMS was applied, with an identification score cutoff of 60%. Additionally, the peaks were searched against an in-house IORA library in both positive and negative mode, using a mass tolerance of 0.01 Da and an identification cutoff of 80%. The data was manually inspected, and identifications without corresponding MS2 spectra were filtered out, except for IORA (ST1 & ST2). Data analysis was performed using Metaboanalyst 5.0 (Pang et al., 2021). The samples were normalized by median and subjected to log transformation. Subsequently, a fold change analysis was performed to detect dysregulated metabolites between secondary spent media compared to primary spent media. Statistical analysis was conducted using a t-test to determine the significance of group differences. Over representation analysis (ORA) was conducted via Metaboanalyst, which calculates enrichment ratio derived from comparing between actual versus predicted number of metabolite hits per super-class metabolite category (Pang et al., 2021). The statistical significance of the enrichment ratios is calculated using hypothesis testing using a binomial distribution to assign a p-value, which is adjusted using Holm’s multiple comparison test (Holm, 1979). Data was visualized using volcano plots generated in R’s ggplot2 package, with a p-value cutoff of <0.01 and a log2(fold change) cut off of > |2|.
[0200] Targeted caffeic acid quantification
[0201] Fannyhessea vaginae culture was grown in NYCIII + 2%FBS for 24-48h at 37°C under anaerobic conditions. Active cultures were then diluted and transferred to fresh NYCIII + 2% FBS or filter-sterilized spent Gardnerella piotii media for 24h. Cultures were then centrifuged to pellet cells, and supernatants filter sterilized (0.22p filter) and submitted for measurement of caffeic acid using mass spectrometry by the Biomolecular Analysis Facility at UVA.
[0202] Initially, 250 pL of each culture media was treated with 1000 pL of 80% methanol kept at -20°C, followed by vortexing for 1 minute and incubation at -20°C for 2 hours to induce protein precipitation. Subsequently, the samples underwent centrifugation at 4°C and 14,000g for 30 minutes, after which the resulting supernatants were transferred to new tubes. These samples were then dried in a speed vac for approximately 5 hours and stored at -80°C until further analysis. Before mass spectrometry analysis, the dried samples were reconstituted in 50 pL of 0.1 % formic acid, and 10 pL of each reconstituted sample was injected for analysis.
[0203] For generating the standard curve, a stock solution of the target molecule, caffeic acid, was prepared at 1 mg / mL in 80% methanol and subsequently diluted down to 1000 ng / mL in 0.1 % formic acid. Serial dilutions were carried out to generate standard curves ranging from 100 ng / mL to 0.01 ng / mL. For analysis, 10 pL of each standard was injected. The mass spectrometer settings were configured with a full scan parameter, including MS1 resolution of 120,000, scan range from 67 to 1000 m / z, RF Lens set at 60, AGC at 25%, and a maximum injection time of 50 ms, all conducted under negative polarity. Additionally, Parallel Reaction Monitoring (PRM) parameters were employed, featuring a collision energy (CE) of 30, resolution set at 50,000, an isolation window of 1.5 m / z, AGC at 50%, and a maximum injection time of 86 ms, also under negative polarity. The mobile phases used were Phase A: 0.1% formic acid in water and Phase B: 0.1% formic acid in 90% methanol.
[0204] The obtained spectra were processed and analyzed using the Skyline software. In this analysis, transitions specific to caffeic acid were included, and the retention time and peak picking were manually assessed for accurate peak area detection. The calculated concentrations were derived from the linear regression equation of the standard curve. To obtain the final concentration of the samples, the calculated values were divided by the sample concentration (5x). This comprehensive methodological approach ensures the accurate and reliable quantification of caffeic acid in the given samples.
[0205] Growth analysis
[0206] Overnight cultures of L iners, P. amnii, P. buccalis, H. timonensis, F. vaginae, A. christensii, G. vaginalis, and G. piotii were cultured under anaerobic conditions for 24-48 hours in NYCIII media + 2% FBS, ODeoo measured, cells pelleted by centrifugation (5,000 rpm, 5 min) and resuspended in fresh NYCIII + 2% FBS. Cultures were then diluted in spent media and aliquoted into a 96-well plate (starting ODeoo -0.05) containing spent or blank media for a kinetic growth assay under anaerobic conditions without shaking. G. piotii and A. christensii’s flocculant phenotype necessitated the use of shaking. There were N=7 replicates per condition for the growth curve data which were distinct samples.
[0207] Compound-specific growth analysis
[0208] To directly probe the relationship between L-histidine and G. piotii growth, G. piotii was cultured under anaerobic conditions for 48 hours in NYCIII + 2% FBS media. OD6oo was measured and bacteria were pelleted via centrifugation (5,000 rpm, 5 min) and resuspended in NYCIII media. Cultures were then diluted in NYCIII media and aliquoted into a 96-well plate (starting ODeoo -0.05) containing either NYCIII or NYCIII + 0.1% filter sterilized L-histidine for a kinetic growth assay under anaerobic conditions with shaking. We quantified growth differences via one-tailed t-test at the NYCIII condition’s max growth time point, in addition to calculating percent growth difference between conditions.
[0209] To assess the influence of propionic acid on the growth kinetics of H. timonensis, a kinetic growth assay was carried out under anaerobic conditions. Propionic acid stocks at a 2x concentration were freshly prepared, filter-sterilized, and anaerobically reduced. Each well of the plates received 100 pL of H. timonensis culture and 100 pL of NYCIII / propionic acid solution, resulting in final propionic acid concentrations of 1 %, 0.1 %, and 0.01% (w / v). Anaerobic conditions were maintained using a breathe-easy membrane, and the plate was agitated at 500 rpm with a shaker that held a Cerillo stratus. Periodic ODe0o readings were taken using the Cerillo stratus to monitor growth kinetics, all normalized to the initial OD reading.
[0210] Data availability
[0211] The data generated during this study is available in a public Github repository: https: / / github.com / lrd3uu / bacterialvaginosis_interactions.
[0212] Code availability
[0213] Code generated during this study is available in a public Github repository: https: / / github.com / lrd3uu / bacterialvaginosis_interactions , and all metabolic network models generated during this study are available in a public Github repository: https: / / github.com / emmamglass / Gardnerella-lnteractions. The contents of both websites are incorporated in their entireties as if fully set forth herein.
[0214] References Related to the Present Disclosure:
[0215] Allsworth, J. E., Lewis, V. A., & Peipert, J. F. (2008). Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sexually Transmitted Diseases, 35(9), 791-796. https: / / doi.Org / 10.1097 / CLQ.0B013E3181788301
[0216] Al-Mushrif, S., Eley, A., & Jones, B. M. (2000). Inhibition of chemotaxis by organic acids from anaerobes may prevent a purulent response in bacterial vaginosis. Journal of Medical Microbiology, 49(11), 1023-1030. https: / / doi.org / 10.1099 / 0022-1317-49-11-1023
[0217] Avery, J. C., & Hoffmann, P. R. (2018). Selenium, Selenoproteins, and Immunity. Nutrients, 10(9), 1203. https: / / doi.org / 10.3390 / nu10091203
[0218] Bonferroni, C. E. (1936). Teoria statistica delle classi e calcolo delle probability. R Istituto Superiors Di Scienze Economiche e Commercial! Di Firenze, 8, 3-62.
[0219] Bradshaw, C. S., & Sobel, J. D. (2016). Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. Journal of Infectious Diseases, 214(Suppl 1), S14-S20. https: / / d0i.0rg / l 0.1093 / i nfd is / ji w 159
[0220] Branco, A. C. C. C., Yoshikawa, F. S. Y., Pietrobon, A. J., & Sato, M. N. (2018). Role of Histamine in Modulating the Immune Response and Inflammation. Mediators of Inflammation, 2018, 9524075. https: / / doi.org / 10.1155 / 2018 / 9524075
[0221] Castro, J., Jefferson, K. K., & Cerca, N. (2019). Innate immune components affect growth and virulence traits of bacterial-vaginosis-associated and non-bacterial-vaginosis- associated Gardnerella vaginalis strains similarly. Pathogens and Disease, 76(9), 1-7. https: / / d0i.0rg / l 0.1093 / femspd / fty089
[0222] Culhane, J. F., Rauh, V., McCollum, K. F„ Elo, I. T„ & Hogan, V. (2002). Exposure to chronic stress and ethnic differences in rates of bacterial vaginosis among pregnant women. American Journal of Obstetrics and Gynecology, 187(5), 1272-1276. https: / / doi.Org / 10.1067 / MCB.2002.127311
[0223] De Seta, F., Campisciano, G., Zanotta, N., Ricci, G., & Comar, M. (2019). The Vaginal Community State Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic Vaginitis. Frontiers in Microbiology, 10, 2451. https: / / doi.org / 10.3389 / fmicb.2019.02451
[0224] Delgado-Diaz, D. J., Tyssen, D., Hayward, J. A., Gugasyan, R„ Hearps, A. C., & Tachedjian, G. (2020). Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. Frontiers in Cellular and Infection Microbiology, 9. https: / / www.frontiersin.org / articles / 10.3389 / fcimb.2019.00446
[0225] Dillard, L. R., Glass, E. M., Lewis, A. L., Thomas-White, K., & Papin, J. A. (2022). Metabolic Network Models of the Gardnerella Pangenome Identify Key Interactions with the Vaginal Environment. M Systems, 8(1), e00689-22. https: / / doi.Org / 10.1128 / msystems.00689-22
[0226] Eade, C. R., Diaz, C., Wood, M. P., Anastos, K., Patterson, B. K., Gupta, P., Cole, A. L., & Cole, A. M. (2012). Identification and Characterization of Bacterial Vaginosis-Associated Pathogens Using a Comprehensive Cervical-Vaginal Epithelial Coculture Assay. PLoS ONE, 7(11). https: / / doi.org / 10.1371 / journal.pone.0050106
[0227] Feehily, C., Crosby, D., Walsh, C. J., Lawton, E. M., Higgins, S., McAuliffe, F. M., & Cotter, P. D. (2020). Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth. Npj Biofilms and Microbiomes, 6(1), 1-9. https: / / doi.Org / 10.1038 / S41522-020-00162-8
[0228] Fettweis, J. M., Serrano, M. G., Brooks, J. P., Edwards, D. J., Girerd, P. H., Parikh, H. I., Huang, B., Arodz, T. J., Edupuganti, L., Glascock, A. L., Xu, J., Jimenez, N. R., Vivadelli,
[0229] 5. C., Fong, S. S., Sheth, N. U., Jean, S., Lee, V., Bokhari, Y. A., Lara, A. M Buck, G. A. (2019). The vaginal microbiome and preterm birth. Nature Medicine, 25(6), Article
[0230] 6. https: / / doi.org / 10.1038 / s41591-019-0450-2
[0231] Fichorova, R. N., Buck, O. R., Yamamoto, H. S., Fashemi, T„ Dawood, H. Y., Fashemi, B., Hayes, G. R., Beach, D. H., Takagi, Y., Delaney, M. L., Nibert, M. L., Singh, B. N., & Onderdonk, A. B. (2013). The villain team-up or how Trichomonas vaginalis and bacterial vaginosis alter innate immunity in concert. Sexually Transmitted Infections, 89(6), 460- 466. https: / / d0i.0rg / l 0.1136 / sextrans-2013-051052
[0232] Forsum, U., Holst, E., Larsson, P. G., Vasquez, A., Jakobsson, T., & Mattsby-Baltzer, I. (2005). Bacterial vaginosis — A microbiological and immunological enigma. APMIS, 113(2), 81-90. https: / / doi.Org / 10.1111 / j.1600-0463.2005.apm1130201.x
[0233] Gajer, P., Brotman, R. M., Bai, G., Sakamoto, J., Schutte, U. M. E., Zhong, X., Koenig, S. S. K., Fu, L., Ma, Z., Zhou, X., Abdo, Z., Forney, L. J., & Ravel, J. (2012). Temporal dynamics of the human vaginal microbiota. Science Translational Medicine, 4(132). https: / / doi.Org / 10.1126 / SCITRANSLMED.3003605
[0234] Goris, J., Konstantinidis, K. T., Klappenbach, J. A., Coenye, T., Vandamme, P., & Tiedje, J. M. (2007). DNA-DNA hybridization values and their relationship to whole-genome sequence similarities. International Journal of Systematic and Evolutionary Microbiology, 57(1), 81-91. https: / / doi.Org / 10.1099 / ijs.0.64483-0
[0235] Holm, S. (1979). A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of Statistics, 6(2), 65-70.
[0236] Horrocks, V., Hind, C. K., Wand, M. E., Fady, P.-E., Chan, J., Hopkins, J. C., Houston, G. L., Tribe, R. M., Sutton, J. M., & Mason, A. J. (n.d.). Nuclear Magnetic Resonance Metabolomics of Symbioses between Bacterial Vaginosis-Associated Bacteria. MSphere, 7(3), e00166-22. https: / / doi.org / 10.1128 / msphere.00166-22
[0237] Janulaitiene, M., Paliulyte, V., Grinceviciene, S., Zakareviciene, J., Vladisauskiene, A., Marcinkute, A., & Pleckaityte, M. (2017). Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis. BMC Infectious Diseases, 17(1), 1-9. https: / / doi.Org / 10.1186 / S12879-017-2501-Y / TABLES / 1
[0238] Jarosik, G. P., Land, C. B., Duhon, P., Chandler, R., & Mercer, T. (1998). Acquisition of Iron by Gardnerella vaginalis. Infection and Immunity, 66(10), 5041-5047.
[0239] Jelinsky, S. A., Choe, S. E., Crabtree, J. S., Cotreau, M. M., Wilson, E., Saraf, K., Dorner, A. J., Brown, E. L., Peano, B. J., Zhang, X., Winneker, R. C., & Harris, H. A. (2008). Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman. BMC Medical Genomics, 1(1), 27. https: / / doi.Org / 10.1186 / 1755-8794- 1 -27
[0240] Jenior, M. L., Glass, E. M., & Papin, J. A. (2023). Reconstructor: A COBRApy compatible tool for automated genome-scale metabolic network reconstruction with parsimonious flux-based gap-filling. Bioinformatics, btad367. https: / / d0i.0rg / l 0.1093 / bioinformatics / btad367 Jenior, M. L., Leslie, J., Kolling, G. L., Archbald-Pannone, L., Powers, D., Petri, W. A., & Papin, J. A. (2023). Systems-ecology designed bacterial consortium protects from severe Clostridioides difficile infection. bioRxiv.
[0241] Kedaigle, A., & Fraenkel, E. (2018). Turning omics data into therapeutic insights. Current Opinion in Pharmacology, 42, 95-101. https: / / doi.Org / 10.1016 / j.coph.2018.08.006
[0242] Kolde, R. (2019). Package “pheatmap”: Pretty heatmaps. Version 1.0.12, 1-8.
[0243] Koumans, E. H., Sternberg, M., Bruce, C., McQuillan, G., Kendrick, J., Sutton, M., & Markowitz, L. E. (2007). The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sexually Transmitted Diseases, 34(11), 864-869. https: / / doi.Org / 10.1097 / QLQ.0B013E318074E565
[0244] Ledgerwood, L. G., Lal, G., Zhang, N., Garin, A., Esses, S. J., Ginhoux, F., Merad, M., Peche, H., Lira, S. A., Ding, Y., Yang, Y., He, X., Schuchman, E. H., Allende, M. L, Ochando, J. C., & Bromberg, J. S. (2008). The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nature Immunology, 9(1), Article 1. https: / / doi.org / 10.1038 / ni1534
[0245] Lele, S., & Richtsmeier, J. T. (1995). Euclidean distance matrix analysis: Confidence intervals for form and growth differences. American Journal of Physical Anthropology, 98(1), 73-86. https: / / doi.org / 10.1002 / ajpa.1330980107
[0246] Letunic, I., & Bork, P. (2021). Interactive Tree Of Life (iTOL) v5: An online tool for phylogenetic tree display and annotation. Nucleic Acids Research, 49(\N1), W293- W296. https: / / d0i.0rg / l 0.1093 / nar / gkab301
[0247] Lieven, C., Beber, M. E., Olivier, B. G., Bergmann, F. T., Ataman, M., Babaei, P., Bartell, J. A., Blank, L. M., Chauhan, S., Correia, K., Diener, C., Drager, A., Ebert, B. E., Edirisinghe, J. N., Faria, J. P., Feist, A. M., Fengos, G., Fleming, R. M. T., Garcia- Jimenez, B., ... Zhang, C. (2020). MEMOTE for standardized genome-scale metabolic model testing. Nature Biotechnology, 38(3), 272-276. https: / / doi.org / 10.1038 / s41587- 020-0446-y
[0248] Liu, Z., Li, L., Fang, Z., Lee, Y„ Zhao, J., Zhang, H„ Chen, W., Li, H„ & Lu, W. (2021). Integration of Transcriptome and Metabolome Reveals the Genes and Metabolites Involved in Bifidobacterium bifidum Biofilm Formation. International Journal of Molecular Sciences, 22(14), 7596. https: / / doi.org / 10.3390 / ijms22147596
[0249] Liu, Xia, Ting Luan, Wanqing Zhou, Lina Yan, Hua Qian, Pengyuan Mao, Lisha Jiang, et al. (2021) The Role of 17p-Estrogen in Escherichia Coli Adhesion on Human Vaginal Epithelial Cells via FAK Phosphorylation. Infection and Immunity 89, no. 11. https: / / doi.Org / 10.1128 / IAI .00219-21.
[0250] Lopes dos Santos Santiago, G., Tency, I., Verstraelen, H., Verheist, R., Trog, M., Temmerman, M., Vancoillie, L, Decat, E., Cools, P., & Vaneechoutte, M. (2012). Longitudinal qPCR study of the dynamics of L. crispatus, L. iners, A. vaginae, (sialidase positive) G. vaginalis, and P. bivia in the vagina. PloS One, 7(9). https: / / doi.org / 10.1371 / JOURNAL.PONE.0045281
[0251] Madden, T. (2002, October 9). The BLAST Sequence Analysis Tool. The NCBI Handbook. https: / / www.ncbi.nlm.nih.gov / books / NBK21097 /
[0252] Madden, T., & Camacho, C. (2021). BLAST+ features. In BLAST® Command Line Applications User Manual [Internet], National Center for Biotechnology Information (US). https: / / www.ncbi.nlm.nih.gov / books / NBK569839 /
[0253] Marrazzo, J. M., Antonio, M., Agnew, K., & Hillier, S. L. (2009). Distribution of Genital Lactobacillus Strains Shared by Female Sex Partners. The Journal of Infectious Diseases, 199(5), 680-683. https: / / doi.org / 10.1086 / 596632
[0254] Mayer, B. T., Srinivasan, S., Fiedler, T. L., Marrazzo, J. M., Fredricks, D. N., & Schiffer, J. T. (2015). Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis. The Journal of Infectious Diseases, 212(5), 793-802. https: / / doi.org / 10.1093 / INFDIS / JIV079
[0255] Mirmonsef, P., Gilbert, D., Zariffard, M., Hamaker, B., Kaur, A., Landay, A., & Spear, G. (2011). The effects of commensal bacteria on innate immune responses in the female genital tract. American Journal of Reproductive Immunology (New York, N.Y. : 1989), 65(3), 190-195. https: / / doi.Org / 10.1111 / j.1600-0897.2010.00943.x
[0256] Murota, K., Nakamura, Y., & Uehara, M. (2018). Flavonoid metabolism: The interaction of metabolites and gut microbiota. Bioscience, Biotechnology, and Biochemistry, 82(4), 600-610. https: / / doi.org / 10.1080 / 09168451.2018.1444467
[0257] Muzny, C. A., & Kardas, P. (2020). A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis. Sexually Transmitted Diseases, 47(7), 441-446. https: / / doi.org / 10.1097 / OLQ.0000000000001178
[0258] Olson, R. D., Assaf, R., Brettin, T., Conrad, N., Cucinell, C., Davis, J. J., Dempsey, D. M., Dickerman, A., Dietrich, E. M., Kenyon, R. W., Kuscuoglu, M., Lefkowitz, E. J., Lu, J., Machi, D., Macken, C., Mao, C., Niewiadomska, A., Nguyen, M., Olsen, G. J Stevens, R. L. (2023). Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): A resource combining PATRIC, IRD and ViPR. Nucleic Acids Research, 57(D1), D678-D689. https: / / doi.org / 10.1093 / nar / gkac1003
[0259] Pang, Z., Chong, J., Zhou, G., de Lima Morais, D. A., Chang, L., Barrette, M., Gauthier, C., Jacques, P.-E., Li, S., & Xia, J. (2021). MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Research, 49(\NV), W388-W396. https: / / doi.Org / 10.1093 / nar / gkab382
[0260] Peebles, K., Velloza, J., Balkus, J. E., McClelland, R. S., & Barnabas, R. V. (2019). High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and MetaAnalysis. Sexually Transmitted Diseases, 46(5), 304-311. https: / / doi.Org / 10.1097 / OLQ.0000000000000972
[0261] Percy, A., Souza, Amanda, Ntai, Ioanna, & Amer, Bashar. (2022). From QC to Quantitation: Utility of QReSS™ Metabolites in FBS Measurements. Cambridge Isotope Laboratories, Inc., Application Note 51. https: / / cil.showpad.com / share / Pfylgul9IIFzYtChsvFrL
[0262] Percy, Andrew, Proos, Robert, & Demianova, Zuzana. (2021). Standardizing Quantitative Metabolomics Analyses Through the QReSS™ Kit. Cambridge Isotope Laboratories, Inc., Application Note 49.
[0263] Pritchard, L., Glover, R. H., Humphris, S., Elphinstone, J. G., & Toth, I. K. (2015). Genomics and taxonomy in diagnostics for food security: Soft-rotting enterobacterial plant pathogens. Analytical Methods, 8(1), 12-24. https: / / doi.org / 10.1039 / C5AY02550H
[0264] Rayman, M. P. (2000). The importance of selenium to human health. The Lancet, 356(9225), 233-241. https: / / doi.org / 10.1016 / S0140-6736(00)02490-9
[0265] Rezaei-Seresht, H., Cheshomi, H., Falanji, F., Movahedi-Motlagh, F., Hashemian, M., & Mireskandari, E. (2019). Cytotoxic activity of caffeic acid and gallic acid against MCF-7 human breast cancer cells: An in silico and in vitro study. Avicenna Journal of Phytomedicine, 9(6), 574-586. https: / / doi.org / 10.22038 / AJP.2019.13475
[0266] Sanchez, Angel Matias, Marina Ines Flamini, Sara Zullino, Santhosh Gopal, Andrea Riccardo Genazzani, and Tommaso Simoncini. (2011) Estrogen Receptor-a Promotes Endothelial Cell Motility through Focal Adhesion Kinase. Molecular Human Reproduction 17, no. 4219-26. https: / / doi.org / 10.1093 / molehr / gaq097.
[0267] Schoch, C. L., Ciufo, S., Domrachev, M., Hotton, C. L., Kannan, S., Khovanskaya, R., Leipe, D., Mcveigh, R., O’Neill, K., Robbertse, B., Sharma, S., Soussov, V., Sullivan, J. P., Sun, L, Turner, S., & Karsch-Mizrachi, I. (2020). NCBI Taxonomy: A comprehensive update on curation, resources and tools. Database: The Journal of Biological Databases and Curation, 2020, baaa062. https: / / doi.org / 10.1093 / database / baaa062
[0268] Schwiertz, A., Taras, D., Rusch, K., & Rusch, V. (2006). Throwing the dice for the diagnosis of vaginal complaints? Annals of Clinical Microbiology and Antimicrobials, 5. https: / / doi.Org / 10.1186 / 1476-0711 -5-4
[0269] Shimaoka, M., Yo, Y., Doh, K., Kotani, Y., Suzuki, A., Tsuji, I., Mandai, M., & Matsumura, N. (2019). Association between preterm delivery and bacterial vaginosis with or without treatment. Scientific Reports, 9(1), 1-8. https: / / doi.org / 10.1038 / s41598-018-36964-2
[0270] Spiegel, C. A., Amsel, R., & Holmes, K. K. (1983). Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. Journal of Clinical Microbiology, 18(V), 170-177. https: / / doi.Org / 10.1128 / jcm.18.1 .170-177.1983 Srinivasan, S., Hoffman, N. G., Morgan, M. T., Matsen, F. A., Fiedler, T. L, Hall, R. W., Ross, F. J., McCoy, C. O., Bumgarner, R., Marrazzo, J. M., & Fredricks, D. N. (2012). Bacterial communities in women with bacterial vaginosis: High resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PloS One, 7(6), e37818. https: / / doi.org / 10.1371 / journal.pone.0037818
[0271] Student. (1908). The Probable Error of a Mean. Biometrika, 6(1), 1-25. https: / / doi.org / 10.2307 / 2331554
[0272] Sun, J., Bi, J., & Kranzler, H. R. (2014). Multi-view singular value decomposition for disease subtyping and genetic associations. BMC Genetics, 15, 73. https: / / doi.org / 10.1186 / 1471- 2156-15-73
[0273] Tachedjian, G., Aldunate, M., Bradshaw, C. S., & Cone, R. A. (2017). The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Research in Microbiologoy, 768(9-10), 782-792. https: / / doi.Org / 10.1016 / j.resmic.2017.04.001
[0274] Thomas-White, K.; Hilt, E. E.; Olmschenk, G.; Gong, M.; Philips, C.; Jarvis, C.; Sanford, N.; White, J.; Navarro, P. An Accurate Metagenomics Pipeline to Characterize Self- Collected Vaginal Microbiome Samples. Preprints 2024, 2024051036. https: / / doi.Org / 10.20944 / preprints202405.1036. v1
[0275] Tortelli, B. A., Lewis, W. G., Allsworth, J. E., Member-Meneh, N., Foster, L. R., Reno, H. E., Peipert, J. F., Fay, J. C., & Lewis, A. L. (2020). Associations between the vaginal microbiome and Candida colonization in women of reproductive age. American Journal of Obstetrics and Gynecology, 222(5), 471 .e 1-471 ,e9. https: / / doi.Org / 10.1016 / J.AJOG.2019.10.008
[0276] Tsugawa, H., Cajka, T., Kind, T., Ma, Y., Higgins, B., Ikeda, K., Kanazawa, M., VanderGheynst, J., Fiehn, O., & Arita, M. (2015). MS-DIAL: Data-independent MS / MS deconvolution for comprehensive metabolome analysis. Nature Methods, 12(6), Article 6. https: / / d0i.0rg / l 0.1038 / nmeth.3393
[0277] Tsugawa, H., Nakabayashi, R., Mori, T., Yamada, Y., Takahashi, M., Rai, A., Sugiyama, R., Yamamoto, H., Nakaya, T., Yamazaki, M., Kooke, R., Bac-Molenaar, J. A., Oztolan-Erol, N., Keurentjes, J. J. B., Arita, M., & Saito, K. (2019). A cheminformatics approach to characterize metabolomes in stable-isotope-labeled organisms. Nature Methods, 16(4), Article 4. https: / / doi.org / 10.1038 / s41592-019-0358-2
[0278] Van der Maaten, L., & Hinton, G. (2008). Visualizing data using t-SNE. Journal of Machine Learning Research, 9(11).
[0279] Vitali, B., Cruciani, & F., Picone, G., Parolin, & C., Donders, & G., & Laghi, & L. (2015). Vaginal microbiome and metabolome highlight specific signatures of bacterial vaginosis. https: / / doi.Org / 10.1007 / S10096-015-2490-y
[0280] Wang, J. (2000). Bacterial vaginosis. Primary Care Update for OB / GYNS, 7(5), 181-185. https: / / doi.Org / 10.1016 / S1068-607X(00)00043-3
[0281] Ward, J. H. (1963). Hierarchical Grouping to Optimize an Objective Function. Journal of the American Statistical Association, 58(301), 236-244. https: / / doi.Org / 10.1080 / 01621459.1963.10500845
[0282] Zhang, S., Guo, Z., Tian, E., Liu, D., Wang, J., & Kong, W. (2022). Meniere disease subtyping: The direction of diagnosis and treatment in the future. Expert Review of Neurotherapeutics, 22(2), 115-127. https: / / doi.org / 10.1080 / 14737175.2022.2030221
[0283] Zhuang, Y„ Wolford, B. N„ Nam, K„ Bi, W„ Zhou, W., Wilier, C. J., Mukherjee, B„ & Lee, S. (2022). Incorporating family disease history and controlling case-control imbalance for population-based genetic association studies. Bioinformatics, 38(18), 4337-4343. https: / / d0i.0rg / l 0.1093 / bioinformatics / btac459
[0284] It should be emphasized that the above-described embodiments are merely examples of possible implementations. Many variations and modifications may be made to the abovedescribed embodiments without departing from the principles of the present disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.
Claims
CLAIMSAt least the following is claimed:1) A method of identifying candidate therapeutics for administration against a candidate bacterial infection, comprising: determining, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determining, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; optionally determining, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control; determining superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data; identifying metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities; clustering the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities; annotating the gene content of each cluster; quantifying the annotated gene content; segregating the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status; identifying genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples; reconstructing the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition; segregating the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species; andidentifying the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species.2) The method of claim 1 , wherein the asymptomatic metagenomic sequencing data of the candidate bacterial infection is the same data as the optional metagenomic sequencing data of a healthy control.3) The method of any one of claims 1 to 2, wherein the candidate bacterial infection is Bacterial Vaginosis (BV).4) The method of any one of claims 1 to 3, further comprising, before determining the taxonomic composition: providing one or more samples of the symptomatic bacterial infection from one or more donors; providing one or more samples of the asymptomatic bacterial infection from one or more donors; optionally providing one or more healthy samples from one or more healthy donors and sequencing the metagenome of the one or more samples of the symptomatic bacterial infection, the metagenome of the one or more samples of the asymptomatic bacterial infection, and optionally the metagenome of the one or more samples of the healthy donor[s],5) The method of any one of claims 1 to 4, wherein the one or more symptomatic samples, one or more asymptomatic samples, and optional one or more healthy samples are vaginal swabs.6) The method of any one of claims 1 to 5, wherein symptomatic status is determined by the presence of excessive discharge and vulvovaginal pruritus.7) The method of any one of claims 1 to 6, wherein asymptomatic status is determined by the absence of excessive discharge and vulvovaginal pruritus.8) The method of any one of claims 1 to 7, wherein the metagenomic sequencing comprises shotgun sequencing, 16S rRNA sequencing, inferred frommetatranscriptome, next-gen sequencing methods, using the 16S rRNA gene as a phylogenetic marker, or shotgun sequencing.9) The method of any one of claims 1 to 8, wherein the superorganism-level functional capacity is determined by: assembling contiguous genomic sequences from the metagenomic sequencing data; annotating gene content by assigning functional pathways to the assembled genomic sequences; mapping metagenomic reads to annotated genes; differentiating functionalities of the mapped metagenomic reads.10) The method of any one of claims 1 to 9, wherein the segregating the quantified gene content is using machine learning.11) The method of claim 10, wherein the machine learning is a random forest or support vector machine.12) The method of any one of claims 1 to 11 , wherein reconstructing the metabolism and segregating the reconstructed metabolism is with genome-scale metabolic network reconstructions.13) The method of one of claims 1 to 12, further comprising: culturing the primary bacterial candidate species; culturing the one or more identified cooperative secondary candidate bacterial species, one or more identified competitive secondary candidate bacterial species, or one or more one or more identified cooperative secondary candidate bacterial species and one or more competitive secondary candidate bacterial species; generating culture metabolomic data of the primary bacterial candidate species culture and each secondary culture; and identifying, from the culture metabolomic data, metabolites from each secondary culture that are dysregulated compared to the primary bacterial candidate species culture.14) The method of any one of claims 1 to 13, further comprising:co-culturing the primary bacterial candidate species with one or more identified cooperative secondary candidate bacterial species, one or more identified competitive secondary candidate bacterial species, or one or more one or more identified cooperative secondary candidate bacterial species and one or more competitive secondary candidate bacterial species; generating metabolomic data of the co-culture; and identifying, from the culture metabolomic data and co-culture metabolomic data, metabolites from each co-culture that are dysregulated compared to the primary bacterial candidate species culture, each secondary candidate bacterial species culture, or any combination of any thereof.15) The method of claim 14, wherein identifying the dysregulated metabolites comprises a fold-change analysis.16) The method of claim 14 or 15, further comprising identifying one or more ligands of each identified dysregulated metabolite.17) The method of any one of claims 1 to 16, wherein the primary bacterial candidate species is a Gardnerella species.18) A system, comprising: a computing device comprising a processor and a memory; and machine-readable instructions stored in the memory that, when executed by the processor, cause the computing device to at least: determine, from provided symptomatic metagenomic sequencing data of a candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the symptomatic bacterial infection; determine, from provided asymptomatic metagenomic sequencing data of the candidate bacterial infection, a taxonomic bacterial composition of one or more samples of the asymptomatic bacterial infection; optionally determine, from provided metagenomic sequencing data of a healthy control, a taxonomic bacterial composition of one or more samples of the healthy control; determine superorganism-level functional metabolic capacity from the symptomatic metagenomic sequencing data, asymptomatic metagenomic sequencing data, and optional healthy metagenomic sequencing data;identify metabolic pathways with differential metabolic capacities between the symptomatic bacterial infection, asymptomatic bacterial infection, and optional healthy control from the determined capacities; cluster the one or more symptomatic samples, one or more asymptomatic samples, and one or more optional healthy samples based on the identified determined functional metabolic capacities; annotate the gene content of each cluster; quantify the annotated gene content; segregate the quantified gene content based on symptomatic status, asymptomatic status, or optional healthy status; identify genes enriched in one or more metabolic pathways from the segregated quantified gene content of the symptomatic sample[s] compared to the asymptomatic samples and optional healthy samples; reconstruct the metabolism of the one or more metabolic pathways from the quantified gene content with gene identities mapped onto one or more species from the determined taxonomic composition; segregate the reconstructed metabolism of the determined taxonomic composition into cooperative or competitive secondary candidate bacterial species in relation to a primary bacterial candidate species; and identify the cooperative and competitive secondary candidate bacterial species from the determined taxonomic composition having cooperative or competitive metabolism with the primary bacterial candidate species.19) The system of claim 18, wherein the asymptomatic metagenomic sequencing data of the candidate bacterial infection is the same data as the optional metagenomic sequencing data of a healthy control.20) The system of claim 18, wherein the candidate bacterial infection is Bacterial Vaginosis (BV).21) The system of any one of claims 18 to 20, wherein the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least, before a determination of the taxonomic composition: sequence the metagenome of the one or more samples of the symptomatic bacterial infection from provided symptomatic data, the metagenome of the one or more samples of the asymptomatic bacterial infection from providedasymptomatic data, and optionally the metagenome of the one or more samples of the healthy data.22) The system of claim 21 , wherein all of the provided data is derived from vaginal swabs.23) The system of any one of claims 18 to 22, wherein symptomatic status is determined by the presence of excessive discharge and vulvovaginal pruritus.24) The system of any one of claims 18 to 23, wherein asymptomatic status is determined by the absence of excessive discharge and vulvovaginal pruritus.25) The system of any one of claims 18 to 24, wherein the metagenomic sequencing comprises shotgun sequencing, 16S rRNA sequencing, inferred from metatranscriptome, next-gen sequencing methods, using the 16S rRNA gene as a phylogenetic marker, or shotgun sequencing.26) The system of any one of claims 18 to 25, wherein the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: determine superorganism-level functional capacity by: assembling contiguous genomic sequences from the metagenomic sequencing data; annotating gene content by assigning functional pathways to the assembled genomic sequences; mapping metagenomic reads to annotated genes; and differentiating functionalities of the mapped metagenomic reads.27) The system of any one of claims 18 to 26, wherein the segregating the quantified gene content is using machine learning.28) The system of claim 27, wherein the machine learning is a random forest or support vector machine.29) The system of any one of claims 18 to 28, wherein reconstruction of the metabolism and segregating the reconstructed metabolism is with genome-scale metabolic network reconstructions.30) The system of any one of claims 18 to 29, wherein the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: identify, from provided culture metabolomic data, metabolites from each secondary culture that are dysregulated compared to the primary bacterial candidate species culture.31) The system of claim 30, wherein identification of the dysregulated metabolites comprises a fold-change analysis.32) The system of any one of claims 18 to 31 , wherein the machine-readable instructions stored in the memory that, when executed by the processor, further cause the computing device to at least: identify one or more ligands of each identified dysregulated metabolite.33) The system of any one of claims 18 to 31 , wherein the primary bacterial candidate species is a Gardnerella species.
Citation Information
Patent Citations
Bacterial identification in clinical infections
US20170058430A1
Method and system for microbiome-derived diagnostics and therapeutics for bacterial vaginosis
US20190367968A1
Treatment of bacterial vaginosis
US20220184154A1
Compounds and pharmaceutical compositions for prevention and / or treatment of dysbiosis and antibacterial antidotes for microbiome-protection
US20220387466A1
Microbiome-based informed method to formulate live biotherapeutics
WO2021076740A1
